Solorank.ai
Login

Cached score snapshot

US.VRTX · Vertex Pharmaceuticals

110分制 59.8/110；5D動能v2 11/50；排序分 70.8/160 · Incomplete inputs

Back to ranking Open volume snapshot
Ranking score 70.8/160
Main score 59.8/110
5D momentum v2 11/50
Rank #143
Setup grade D 36.1

Score breakdown

觀望

Medium twelvedata

Score and price trend

D 36.1 Technical A · Low sample confidence

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

0 40 80 110 Score 05-13 07-28 08-21 09-04 09-18 $408.00$495.07$582.14 Price Projection date
Historical projection
Model Median P25/P75 歷史相似情境上漲比例 Down5 Actual / compare
Rolling DOE best · score 2.578 · anchors 120 +1.39% -0.97% / +2.92% 62.5% 1.3% Actual +5.98% · vs median +4.59% · inside 25-75 band
30D observation +7.98% +3.61% / +12.41% 90% 2.5% Actual outcome pending · 1 / 30 bars observed
Historical projection 10D n=160 +0.57% -1.66% / +2.67% 55% 3.8% Actual outcome pending · 1 / 10 bars observed

歷史情境統計基於已存檔相似 setup；圖中投影中位線為統計中位數的線性插值展示，並非價格路徑預測或買賣建議。

2026-05-13 → 2026-09-18 · 201 archived points · 4 Improving turn signal · 4 Deteriorating signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 70.8
Display grade 觀望
Model version cursor_18_27_news_v2_160
Main score 59.8/110 (觀望)
5D momentum v2 11/50 (弱)
Score with momentum v2 70.8/160 (低排序)
Risk level Medium

Audit trace

Full calculation detail

Calculation detail · 8 sections

Incomplete score

此 snapshot 已計出評分，但以下輸入仍不完整；缺失維度以 0 分處理，請留意 audit 明细。

  • VIX_MISSING: VIX market context is required for market environment scoring

Market inputs

Bar count 60
ma20 480.836
ma50 473.1562
close 496.07
prevClose 484.03
avgVolume20 1317605
volumeRatio 0.75
changePercent 2.49

Metrics snapshot

close 496.07
volume 992400
changePercent 2.49

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 59.8/110
Main rating 觀望
5D momentum v2 11/50
Score with momentum v2 70.8/160
Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 3.8/5 · 良好
Dimension score 3.8/5
Dimension grade 良好

Sub-items

pbPoints 0.2
pePoints 0.2
epsPoints 0
roePoints 0.75
debtPoints 0.5
marginPoints 0.75
turnoverUsdM 492.2999
volumePoints 0.5
revenuePoints 0.4
dividendPoints 0
marketCapPoints 0.5

資金流 — 10/20 · 較差
Dimension score 10/20
Dimension grade 較差

Sub-items

cmfPoints 0.8
mfiPoints 2.4
obvPoints 1.6
vwapPoints 3.2

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL
symbol US.VRTX
message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.
optional true
holderCount n/a
holderPoints 2
top10ShareRatio n/a
concentrationPenalty 0
institutionPoints 2

市場環境 — 7.2/15 · 較差
Dimension score 7.2/15
Dimension grade 較差

Sub-items

vix

score 0

details

source twelvedata+fred
missing true
vixClose n/a

trend

score 3.4

details

qqq

ma20 700.3395
ma50 714.5674
name QQQ
close 723.03
points 1.4

spy

ma20 750.1725
ma50 747.189
name SPY
close 773.26
points 2
source twelvedata+fred
atrPct 2.6724
atrPoints 3
cciPoints 0.8
vixPoints 0
marketTrendPoints 3.4

催化劑 — 2/20 · 較差
Dimension score 2/20
Dimension grade 較差

Sub-items

catalyst

score 2

details

source finnhub_news_keyword_model
articleCount 8
catalystCount 0
catalystPoints 2

風險管理 — 7.2/10 · 良好
Dimension score 7.2/10
Dimension grade 良好

Sub-items

position

score 1.6

details

atrPct 2.6724
turnoverUsdM 492.2999
liquidityPoints 0.6
volatilityPoints 1
rrPoints 1.8

stopLevels

symbol US.VRTX
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 469.5558

strength_details

ma_score 2
atr_score 2
rsi_score 3
macd_score 3
volume_score 1
market_adjustment 1
risk_reward_ratio 1.7
stop_loss_percent 5.3
take_profit_price 539.8184
target_multiplier 2.2
technical_strength 2.25
take_profit_percent 8.8
positionPoints 1.6
stopLossPoints 1.8

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.6464
stopLossPercent 5.3449
diversificationPoints 2

技術信號 — 23.6/30 · 良好
Dimension score 23.6/30
Dimension grade 良好

Sub-items

bbPoints 3
adxPoints 3
sarPoints 2.4
vcpPoints 2.2
macdPoints 4

vcpPayload

vcp_pass false
vcp_score 2.2
vcp_reason 波幅收縮(13.8%→5.7%)；跌縮量(近10日5日)；站上MA50；Ready=Y；Confirm=N

vcp_metrics

up_days 4
vol_ref 1743350
down_days 5
vcp_ready true
above_ma50 true
avg_vol_10 1417730
avg_vol_20 1339495
avg_vol_30 1743350
range_pct_10 0.0566
range_pct_20 0.0684
range_pct_30 0.1384
up_expand_ok false
lookback_used 59
near_20d_high true
contraction_ok true
down_shrink_ok true
up_expand_days 1
breakout_20d_ok false
vol_ratio_10_30 0.8132
dist_to_20d_high 0.0057
down_shrink_days 5
breakout_level_20d 498.91
vcp_breakout_confirm false
contraction_ratio_10_30 0.4092
vcp_name_en Volatility Contraction Pattern
vcp_name_zh 波動收縮形態
vol_contraction true
kdjAdxPoints 0.8
rsiKdjPoints 4
volumeWeight 2
maCrossPoints 2.4
shortRsiPoints 1
shortMacdPoints 0.4
volConfirmPoints 0
volumePointsTechnical 0.4

情緒分析 — 6/10 · 一般
Dimension score 6/10
Dimension grade 一般

Sub-items

sentiment

score 6

details

source finnhub_news_keyword_model
articleCount 8
negativeHits 0
positiveHits 4
sentimentScoreRaw 1.2

sentimentData

raw {"id":141111809,"url":"https://finnhub.io/api/news?id=c75088a93dadcf9e8e98257af8b682dac1d13336bde4d21c44821d1d977692b6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex's Q2 earnings miss estimates, but revenues beat. It lifts its 2026 sales outlook, and sees growing contributions from newer products.","category":"company","datetime":1785855420,"headline":"VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised"}, {"id":141110156,"url":"https://finnhub.io/api/news?id=f3baecf2b44e7c92410111d5cff7381e367457398aba185e3d320a8c7d034127","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex raises its 2026 revenue outlook as CF growth, newer products and a near-term renal launch strengthen its diversification push.","category":"company","datetime":1785852000,"headline":"VRTX Q2 Earnings Call Highlights Launch Momentum & Higher Outlook"}, {"id":141107841,"url":"https://finnhub.io/api/news?id=21c2ae1e0954cdae5c7b9195cab02ce3174708240085a53081522118a8c97864","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals (NasdaqGS:VRTX) has agreed to acquire Crinetics Pharmaceuticals in a deal expected to close in the third quarter of 2026. The transaction is designed to broaden Vertex's reach in biotech and add new disease areas beyond its core cystic fibrosis franchise. Investors are watching for the potential impact on Vertex's drug pipeline and competitive position as the companies work toward closing. Vertex Pharmaceuticals enters this deal with a sizeable track record in cystic...","category":"company","datetime":1785841838,"headline":"Vertex (VRTX) Buys Crinetics To Push Beyond Cystic Fibrosis"}, {"id":141106171,"url":"https://finnhub.io/api/news?id=dd56684479086b09a9c08b3176c470d1855c316ea8c11773c551232e8fcd3c7d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex raises full-year 2026 revenue guidance to $13.1-$13.2 billion as CASGEVY and JOURNAVX show strong sequential growth, while advancing a robust pipeline and strategic Crinetics acquisition.","category":"company","datetime":1785820106,"headline":"Vertex Pharmaceuticals Inc (VRTX) (Q2 2026) Earnings Call Highlights: Revenue Surges 12% to $3. ..."}, {"id":141105354,"url":"https://finnhub.io/api/news?id=7e00387653f41c77398a88e148bbf63751fee590b653e4f81ecdb065f240f8c5","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"VRTX","summary":"Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call August 3, 2026 4:30 PM EDTCompany ParticipantsSusie Lisa - Senior Vice President of...","category":"company","datetime":1785798598,"headline":"Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call Transcript"}, {"id":141104290,"url":"https://finnhub.io/api/news?id=2c85fd6651e8a37c93bd116754644b8c8fdc608ac20c6dd3606025ce523510da","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.","category":"company","datetime":1785792601,"headline":"Vertex (VRTX) Reports Q2 Earnings: What Key Metrics Have to Say"}, {"id":141104291,"url":"https://finnhub.io/api/news?id=3312282938d1eebf9e011d1fbb4c0cede96428eca208a72aa3620cc06e6c5b8a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex (VRTX) delivered earnings and revenue surprises of -1.25% and +3.32%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?","category":"company","datetime":1785792003,"headline":"Vertex Pharmaceuticals (VRTX) Q2 Earnings Lag Estimates"}, {"id":141103108,"url":"https://finnhub.io/api/news?id=2107a32523531702676a61163a0ada3a64e71398d16b7a18148ca98956bb5707","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) announced better-than-expected revenue in Q2 CY2026, with sales up 12.5% year on year to $3.33 billion. The company’s full-year revenue guidance of $13.15 billion at the midpoint came in 0.7% above analysts’ estimates. Its non-GAAP profit of $4.73 per share was in line with analysts’ consensus estimates.","category":"company","datetime":1785789407,"headline":"Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q2 CY2026 Sales Expectations, Full-Year Outlook Slightly Exceeds Expectations"}
raw_source {"id":141163533,"url":"https://finnhub.io/api/news?id=3b7a86f6ceb88fe11df34224171d2e64d74b5e8b7d5f7a718f923ea58fe91d9c","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1160013511/image_1160013511.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"VRTX","summary":"Tweedy Browne’s Q2 2026 13F: $1.32B portfolio, top holdings & new Zoetis stake, plus trims/exits and concentration insights—read now.","category":"company","datetime":1786229949,"headline":"Tracking Tweedy Browne Portfolio - Q2 2026 Update"}, {"id":141150935,"url":"https://finnhub.io/api/news?id=f30205fda5e3671faae31aaf11b68289bc37bc3003af8d9080eae74361b10542","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"This risk is weighing on the stock.","category":"company","datetime":1786126800,"headline":"Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire?"}, {"id":141148212,"url":"https://finnhub.io/api/news?id=f1429036e90b90226a0f1548de75810532846ed909768a41040c55c430c961bf","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Management has just raised the peak-sales estimate, and a large slice of it belongs to a drug still running Phase III trials.","category":"company","datetime":1786117197,"headline":"What Insmed Stock's Premium Is Actually Buying"}, {"id":141135446,"url":"https://finnhub.io/api/news?id=fd1d07072af0353df58d8c6462fe44867241410e634aa7fe7a706972fa6edc43","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"IONQ posts a wider-than-expected Q2 loss but tops revenue estimates, raises its 2026 revenue outlook and sees shares rise after the results.","category":"company","datetime":1786027140,"headline":"IONQ Q2 Earnings Miss Estimates, Revenues Beat, Stock Rises"}, {"id":141134178,"url":"https://finnhub.io/api/news?id=d3341145831fa1164ba72987649fc3f9cde6dfde5df1d47e24be44aed8cc7b65","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Study confirms western salt structure, identifies an eastern exploration target and establishes a staged technical pathway for further evaluationVANCOUVER, British Columbia, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce, further to its news release dated July 16, 2026, that it has received the final technical study prepared by Lonquist Field Service (Canada), ULC (“Lonquist”) for the Company’s Robinson","category":"company","datetime":1786017600,"headline":"Vortex Energy Receives Final Technical Study Results for the Robinsons River Salt Project"}, {"id":141131676,"url":"https://finnhub.io/api/news?id=42acecf7bad1baa7ec04cb7ac59418a1c1004daf4cddd4cce6da65363ef901db","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"AbCellera Biologics Inc (ABCL) advances ABCL-635 with early phase 2 completion and secures over $110 million in new T-cell engager deals, despite a wider net loss and revenue decline.","category":"company","datetime":1785992501,"headline":"AbCellera Biologics Inc (ABCL) (Q2 2026) Earnings Call Highlights: Strong Pipeline Progress and ..."}, {"id":141129231,"url":"https://finnhub.io/api/news?id=dcdf3ce3fb9a9978376d50e78da86431a8757aa1e827d9ec985228c198f4b841","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"AbCellera Biologics (NASDAQ:ABCL) said it expects to report top-line data “very soon” from its Phase I study of ABCL635, an antibody being evaluated for moderate-to-severe vasomotor symptoms, or hot flashes, associated with menopause. President and Chief Executive Officer Dr. Carl Hansen said enrol","category":"company","datetime":1785967428,"headline":"AbCellera Biologics Q2 Earnings Call Highlights"}, {"id":141128774,"url":"https://finnhub.io/api/news?id=2a2a2d7e0c3b0c4acf97cdb30edff26305271e2d709137a8518fb82aaeb34cfe","image":"","source":"Benzinga","related":"VRTX","summary":"Truist Securities analyst Danielle Brill maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $560 to $565.","category":"company","datetime":1785938692,"headline":"Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $565"}, {"id":141120403,"url":"https://finnhub.io/api/news?id=f62b2e86c4216e2bda2377255cef430a7f277cbdefbb4b3b2c17c9278e69b758","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"-- Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- -- Company to report ELEVATE-45-201 Cohort 1 data in October 2026 -- -- ELEVATE-45-201 Cohort 2 dosing ongoing at the increased dose of 10 mg/kg with data expected in H1 2027 -- -- Vertex to report VX-670 Phase 1/2 data in people living with DM1 in H2 2026 -- BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc","category":"company","datetime":1785927600,"headline":"Entrada Therapeutics Reports Second Quarter 2026 Financial Results"}, {"id":141121678,"url":"https://finnhub.io/api/news?id=5248f37b608df4175afdacfec21505a887b9d7e62e088904934c0a4a097c8b4d","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2288169175/image_2288169175.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"VRTX","summary":"CRISPR Therapeutics (CRSP) remains a Strong Buy, supported by robust CASGEVY sales growth and pipeline expansion.","category":"company","datetime":1785924544,"headline":"CRISPR: \"Strong Buy\" CASGEVY Sales Growth And In Vivo Expansion With CTX310"}, {"id":141128775,"url":"https://finnhub.io/api/news?id=4a00fc07417e00a900782dede2c3227b5bb2ffd5494048eb5e0a007a66482462","image":"","source":"Benzinga","related":"VRTX","summary":"Barclays analyst Eliana Merle maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $615 to $617.","category":"company","datetime":1785922255,"headline":"Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $617"}, {"id":141111807,"url":"https://finnhub.io/api/news?id=e47001faa115166263a442f28230abdba42b95d19b8edb04e4fd9ecec1553469","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals (VRTX) remains well positioned heading into the second half of 2026 as severa","category":"company","datetime":1785863115,"headline":"Vertex Pharmaceuticals Seen Well Positioned Ahead of Pipeline Catalysts, UBS Says"}, {"id":141111808,"url":"https://finnhub.io/api/news?id=1779ffa16d4cf28c1b259ac324be9f15ee814476b807b5bf97951a8231ca3e17","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals (VRTX) reported a solid Q2 and raised its outlook, highlighting the strength","category":"company","datetime":1785859337,"headline":"Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says"}, {"id":141110155,"url":"https://finnhub.io/api/news?id=ab934a24772cacbc2444176e33fe2e26a3432801ece501642cda46733319fe6f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex stock regained its footing Tuesday, rising on a strong second-quarter report and amid heightened expectations for its kidney disease treatment.","category":"company","datetime":1785855630,"headline":"How Vertex Regained Its Footing On A Competitor's Bullish Report"}, {"id":141111809,"url":"https://finnhub.io/api/news?id=c75088a93dadcf9e8e98257af8b682dac1d13336bde4d21c44821d1d977692b6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex's Q2 earnings miss estimates, but revenues beat. It lifts its 2026 sales outlook, and sees growing contributions from newer products.","category":"company","datetime":1785855420,"headline":"VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised"}, {"id":141110509,"url":"https://finnhub.io/api/news?id=f6f657f73b56d365c3988923bf6a3d9124e87491e39b6391d0a32defb58016c3","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"CRSP reports a narrower-than-expected Q2 loss. Revenues beat estimates as Casgevy sales surge across global markets and clinical programs advance.","category":"company","datetime":1785855360,"headline":"CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates"}, {"id":141110156,"url":"https://finnhub.io/api/news?id=f3baecf2b44e7c92410111d5cff7381e367457398aba185e3d320a8c7d034127","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex raises its 2026 revenue outlook as CF growth, newer products and a near-term renal launch strengthen its diversification push.","category":"company","datetime":1785852000,"headline":"VRTX Q2 Earnings Call Highlights Launch Momentum & Higher Outlook"}, {"id":141120404,"url":"https://finnhub.io/api/news?id=536ca1939192aa75d5e6bab55534f6b569982fd11bc66824814b4cc31c74a4a9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Moby summary of Vertex Pharmaceuticals Incorporated's Q2 2026 earnings call","category":"company","datetime":1785846600,"headline":"Vertex Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary"}, {"id":141128776,"url":"https://finnhub.io/api/news?id=a0e8acf95ce40887b103881fce5237ca4516cca5aecd8d5b7c448a54203438f4","image":"","source":"Benzinga","related":"VRTX","summary":"TD Cowen analyst Phil Nadeau maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $525 to $550.","category":"company","datetime":1785846489,"headline":"TD Cowen Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $550"}, {"id":141111811,"url":"https://finnhub.io/api/news?id=e0958b66343c41ec1dc90eccdc735fecb25accfdb235add8df6547d345ab61de","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Despite another strong earnings report, analysts warned that upcoming cystic fibrosis data from Sionna Therapeutics \"looms large\" over Vertex.","category":"company","datetime":1785845940,"headline":"Vertex’s biggest overhang: a rival 50 times smaller"}, {"id":141107841,"url":"https://finnhub.io/api/news?id=21c2ae1e0954cdae5c7b9195cab02ce3174708240085a53081522118a8c97864","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals (NasdaqGS:VRTX) has agreed to acquire Crinetics Pharmaceuticals in a deal expected to close in the third quarter of 2026. The transaction is designed to broaden Vertex's reach in biotech and add new disease areas beyond its core cystic fibrosis franchise. Investors are watching for the potential impact on Vertex's drug pipeline and competitive position as the companies work toward closing. Vertex Pharmaceuticals enters this deal with a sizeable track record in cystic...","category":"company","datetime":1785841838,"headline":"Vertex (VRTX) Buys Crinetics To Push Beyond Cystic Fibrosis"}, {"id":141107179,"url":"https://finnhub.io/api/news?id=06027c260ce9de9f61eb87edc3fd3f074dda0e76b30bcca2da7b0e57104fa68b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Crinetics Pharmaceuticals stock has delivered very strong gains over the past few years, yet the current valuation checks point to a market price that leans expensive rather than clearly cheap. Crinetics Pharmaceuticals has returned about 384% over the past 3 years, which puts recent enthusiasm for the stock firmly in focus for anyone thinking about upside from here. Vertex Pharmaceuticals' agreement to acquire Crinetics and the regulatory progress for atumelnant can support high...","category":"company","datetime":1785834837,"headline":"Crinetics Pharmaceuticals (CRNX) Stock Looks Pricey As Buyout News Lands"}, {"id":141110584,"url":"https://finnhub.io/api/news?id=83f00ed155351fa091931ebd6f19d490a2410a74beb0fca26cc0781a757d8552","image":"","source":"Benzinga","related":"VRTX","summary":"Cantor Fitzgerald analyst Carter Gould maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $590 to $595.","category":"company","datetime":1785831893,"headline":"Cantor Fitzgerald Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $595"}, {"id":141107416,"url":"https://finnhub.io/api/news?id=79c24c254426f5197e92c42652e8d662216c9656ed34db5290a7b518a70f7c0b","image":"","source":"SeekingAlpha","related":"VRTX","summary":"","category":"company","datetime":1785826663,"headline":"Vertex Pharmaceuticals: A Transition Year Into A Multi-Franchise Growth Story"}, {"id":141106171,"url":"https://finnhub.io/api/news?id=dd56684479086b09a9c08b3176c470d1855c316ea8c11773c551232e8fcd3c7d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex raises full-year 2026 revenue guidance to $13.1-$13.2 billion as CASGEVY and JOURNAVX show strong sequential growth, while advancing a robust pipeline and strategic Crinetics acquisition.","category":"company","datetime":1785820106,"headline":"Vertex Pharmaceuticals Inc (VRTX) (Q2 2026) Earnings Call Highlights: Revenue Surges 12% to $3. ..."}, {"id":141105354,"url":"https://finnhub.io/api/news?id=7e00387653f41c77398a88e148bbf63751fee590b653e4f81ecdb065f240f8c5","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"VRTX","summary":"Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call August 3, 2026 4:30 PM EDTCompany ParticipantsSusie Lisa - Senior Vice President of...","category":"company","datetime":1785798598,"headline":"Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call Transcript"}, {"id":141104289,"url":"https://finnhub.io/api/news?id=c7c1bac8a4be7e1bca887af4abc9e92a06d03ce636155d166171dc8851c4e126","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals (NASDAQ:VRTX) reported second-quarter 2026 revenue growth of 12% year over year to $3.3 billion, driven by continued growth in its cystic fibrosis franchise and rising contributions from newer products CASGEVY and JOURNAVX. Chief Executive Officer and President Reshma Kewalra","category":"company","datetime":1785798229,"headline":"Vertex Pharmaceuticals Q2 Earnings Call Highlights"}, {"id":141105291,"url":"https://finnhub.io/api/news?id=cd71711e25cb163c9f05f483851c9f5b6b7eb81c55fa46d409773ec5676efefb","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"VRTX","summary":"2026-08-03. The following slide deck was published by Vertex Pharmaceuticals Incorporated in conjunction with their 2026 Q2 earnings call.","category":"company","datetime":1785798079,"headline":"Vertex Pharmaceuticals Incorporated 2026 Q2 - Results - Earnings Call Presentation"}, {"id":141104290,"url":"https://finnhub.io/api/news?id=2c85fd6651e8a37c93bd116754644b8c8fdc608ac20c6dd3606025ce523510da","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.","category":"company","datetime":1785792601,"headline":"Vertex (VRTX) Reports Q2 Earnings: What Key Metrics Have to Say"}, {"id":141104291,"url":"https://finnhub.io/api/news?id=3312282938d1eebf9e011d1fbb4c0cede96428eca208a72aa3620cc06e6c5b8a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex (VRTX) delivered earnings and revenue surprises of -1.25% and +3.32%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?","category":"company","datetime":1785792003,"headline":"Vertex Pharmaceuticals (VRTX) Q2 Earnings Lag Estimates"}, {"id":141103107,"url":"https://finnhub.io/api/news?id=98a2abcf301231bc0d0aaead7b8926e9c78fdfcb82c76cbbb0cc6e889ba5bb06","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex stock dipped late Monday on a mixed second-quarter report. But the biotech giant raised its sales guidance for the year.","category":"company","datetime":1785790435,"headline":"Vertex Raises 2026 Guidance, But Shares Dip For One Key Reason"}, {"id":141103108,"url":"https://finnhub.io/api/news?id=2107a32523531702676a61163a0ada3a64e71398d16b7a18148ca98956bb5707","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) announced better-than-expected revenue in Q2 CY2026, with sales up 12.5% year on year to $3.33 billion. The company’s full-year revenue guidance of $13.15 billion at the midpoint came in 0.7% above analysts’ estimates. Its non-GAAP profit of $4.73 per share was in line with analysts’ consensus estimates.","category":"company","datetime":1785789407,"headline":"Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q2 CY2026 Sales Expectations, Full-Year Outlook Slightly Exceeds Expectations"}, {"id":141103109,"url":"https://finnhub.io/api/news?id=c2b5656a468d8791f71fe09a62a59cf02bfd34ac2e88a2aafd4178787e8d1233","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Announced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net of Estimated Cash Acquired PALSONIFY® (Paltusotine) Net Product Revenue of $24.0 Million for Second-Quarter 2026 SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumor","category":"company","datetime":1785787500,"headline":"Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update"}, {"id":141103110,"url":"https://finnhub.io/api/news?id=b906634ef71b39efd517bbbaafd8f51cefd4da9cb3e99c193c693beb458b10fa","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"BOSTON, August 03, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2026, and updated its full year 2026 revenue guidance.","category":"company","datetime":1785787260,"headline":"Vertex Reports Second Quarter 2026 Financial Results"}, {"id":141102404,"url":"https://finnhub.io/api/news?id=939a925a360f140b82437bcf1c066f9578c7f6d8d02242dd6344b422c5f7a75f","image":"","source":"Benzinga","related":"VRTX","summary":"Vertex Pharmaceuticals (NASDAQ:VRTX) raises FY2026 sales outlook from $12.950 billion-$13.100 billion to $13.100 billion-$13.200 billion vs $13.065 billion estimate.","category":"company","datetime":1785772904,"headline":"Vertex Pharmaceuticals Raises FY2026 Sales Guidance from $12.950B-$13.100B to $13.100B-$13.200B vs $13.065B Est"}, {"id":141102405,"url":"https://finnhub.io/api/news?id=d851715324594ca0a83a36932e5f194d1100c4a171088992edaa84adad7f327d","image":"","source":"Benzinga","related":"VRTX","summary":"Vertex Pharmaceuticals (NASDAQ:VRTX) reported quarterly earnings of $4.73 per share which met the analyst consensus estimate. This is a 4.65 percent increase over earnings of $4.52 per share from the same period last","category":"company","datetime":1785772886,"headline":"Vertex Pharmaceuticals Q2 Adj. EPS $4.73, Inline, Sales $3.334B Beat $3.232B Estimate"}, {"id":141101633,"url":"https://finnhub.io/api/news?id=210dc9eadb0f1e641b405b20d701188a86b5d7a5db961e15cc5ee67a2573203c","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2231767274/image_2231767274.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"VRTX","summary":"Big Tech's earnings reports laid bare a growing divide in the market's appetite for AI spending. Investors now focus on results from industrials, health care, consumer staples/discretionary.","category":"company","datetime":1785766800,"headline":"Divided Tech, Divided Fed: Navigating AI Capex Scrutiny And Mixed Macro Signals"}, {"id":141098887,"url":"https://finnhub.io/api/news?id=48d0b35462c58b56f76fb282a857a48a7324ea7d8a8bec1032ce82a8f07a63bf","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Wall Street futures pointed moderately higher pre-bell Monday after President Donald Trump, over the","category":"company","datetime":1785755481,"headline":"Falling Oil Boosts Wall Street Pre-Bell; Asia Mixed, Europe Up"}, {"id":141099604,"url":"https://finnhub.io/api/news?id=0b813f41b7078cecf12b4aafa9a2ca131b75aa021fa9c19c50adbd14d08635cb","image":"https://cdn.benzinga.com/files/images/story/2026/08/03/TysonFoods.jpg?width=2048&height=1536","source":"Benzinga","related":"VRTX","summary":"U.S. stock futures up, focus on earnings from Tyson Foods, Marriott, Universal Logistics, Williams Companies, and Vertex Pharmaceuticals.","category":"company","datetime":1785724052,"headline":"Tyson Foods, Marriott And 3 Stocks To Watch Heading Into Monday"}, {"id":141100201,"url":"https://finnhub.io/api/news?id=bad502596ada943e824fa1a41cadb663072846cc663445ce8eab7c42d8dbcca9","image":"https://cdn.benzinga.com/files/images/story/2026/08/03/Fear-and-Greed.jpg?width=2048&height=1536","source":"Benzinga","related":"VRTX","summary":"CNN Money Fear & Greed index improved while remaining in 'Fear' zone on Friday. Amazon up 15%, Apple down 7%.","category":"company","datetime":1785723704,"headline":"Nasdaq Jumps 1% as Amazon Shares Surge: Investor Sentiment Improves, But Greed Index Remains in 'Fear' Zone"}, {"id":141091494,"url":"https://finnhub.io/api/news?id=fab83185dfc322c5138a32b43f26849a509ecd83026c58227dad50ddfd0cb7aa","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results this Monday after the bell. Here’s what to look for.","category":"company","datetime":1785645417,"headline":"Vertex Pharmaceuticals (VRTX) Q2 Earnings Report Preview: What To Look For"}, {"id":141081582,"url":"https://finnhub.io/api/news?id=fbee925dabbe6f460ef2b4b28c54e17bf35b8224f7677ab26790e7608838499f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"The biotech's shares have stumbled after a guidance change, and investors are weighing whether this is the moment to step in or step aside.","category":"company","datetime":1785526149,"headline":"Is The Recent Pullback In Alnylam Stock An Opportunity Or A Trap?"}, {"id":141072827,"url":"https://finnhub.io/api/news?id=eb8ae6cb70ca7b946707a8aa4b6c4d3c77225f489baa605fe36f3ca8cc64e515","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"There are other reasons to pay attention to Viking Therapeutics.","category":"company","datetime":1785451800,"headline":"Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target"}, {"id":141057143,"url":"https://finnhub.io/api/news?id=421d31ea5999d389b5893a796c7ed1557f77b278da24643c864ae1a8d7df7f3a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals (VRTX) is back in focus after AbCellera Biologics announced a collaboration to develop multispecific T cell engagers targeting autoimmune diseases and other conditions. Under the agreement, Vertex will fund the research and retain commercialization rights. See our latest analysis for Vertex Pharmaceuticals. The latest AbCellera collaboration comes as Vertex Pharmaceuticals' share price has risen 15.87% over the past 90 days and the 5 year total shareholder return sits...","category":"company","datetime":1785352120,"headline":"Vertex Pharmaceuticals (VRTX) Expands Its Pipeline Reach, Is The Stock Fully Valued?"}, {"id":141055852,"url":"https://finnhub.io/api/news?id=af8516feb80f1c0c63d5e073b11c8faedae64310cc396f9cbb7780cbc28736e3","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals has delivered a 145.1% return over the past five years, yet its current valuation picture is mixed, as a Discounted Cash Flow (DCF) intrinsic value estimate points to meaningful upside while market-based multiples look closer to fair. Over five years, Vertex Pharmaceuticals has returned 145.1%, which puts the current share price in a very different place compared with where long-term holders started. Expectations for continued cash generation from its existing...","category":"company","datetime":1785341297,"headline":"Vertex Pharmaceuticals (VRTX) Stock Looks Like A Bargain At This Price"}, {"id":141054235,"url":"https://finnhub.io/api/news?id=ec84f806f9b56e49cb76104e77c2ce400a7ef3f40a464d06bfad72fa6a3adbbf","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Evaluate the expected performance of Vertex (VRTX) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.","category":"company","datetime":1785330924,"headline":"Vertex (VRTX) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates"}, {"id":141054236,"url":"https://finnhub.io/api/news?id=de94bed6584f5074d58e85040ba27013c8626725d9b5c8153c69645b52623247","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"The deal adds to a growing streak of partnerships involving new types of T cell engagers and gives Vertex another chance to broaden a business still reliant on cystic fibrosis medicines.","category":"company","datetime":1785325200,"headline":"AbCellera, Vertex partner on next-gen T-cell engagers"}, {"id":141052195,"url":"https://finnhub.io/api/news?id=60bbb3013ffab29675f18d6859109afcd760881dfa67d13bb4615ac423d1506e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"VANCOUVER, British Columbia, July 29, 2026--AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions","category":"company","datetime":1785322800,"headline":"AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions"}, {"id":141051677,"url":"https://finnhub.io/api/news?id=58593945567739718700c0a3f06ba07fe7dd080a3f1abae5a528f461dd26e8eb","image":"https://www.chartmill.com/images/uploads/Strong_Growth_500_264px_webp_8f1ee6ba5b.webp","source":"ChartMill","related":"VRTX","summary":"Vertex Pharmaceuticals (VRTX) combines strong earnings growth, zero debt, and a consolidating technical pattern, making it a textbook breakout candidate for growth investors.","category":"company","datetime":1785319828,"headline":"Vertex Pharmaceuticals (NASDAQ:VRTX): Strong Growth and Textbooks Technical Setup for Breakout"}, {"id":141048348,"url":"https://finnhub.io/api/news?id=7172b274a14c0e365b0221f98cf8730f87f861736eeece3e6e1d313c5bc1f022","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $490.39, moving +2.38% from the previous trading session.","category":"company","datetime":1785275405,"headline":"Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider"}, {"id":141043741,"url":"https://finnhub.io/api/news?id=7f74e4b608d0430ce273cd33af9179a12f910b9aa7dd3269cbb77c4b0b1085f6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.","category":"company","datetime":1785247226,"headline":"Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for"}, {"id":141043769,"url":"https://finnhub.io/api/news?id=b7dde44202e682107701df8a3cf25cac7d7d55413e6642c4ec20852be2744635","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.","category":"company","datetime":1785243604,"headline":"Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know"}, {"id":141044941,"url":"https://finnhub.io/api/news?id=85487e655fb89144a8a6f022c19cdb5c978e7d32417f8c31520957270297579f","image":"https://image.cnbcfm.com/api/v1/image/108340810-260727-Chris_Young__Vertex_CEO.jpg?v=1785190743&w=1920&h=1080","source":"CNBC","related":"VRTX","summary":"Vertex CEO Chris Young told Jon Fortt tax compliance is being remade by AI, e-invoicing mandates and agentic commerce – but tax has to stay deterministic, so AI wraps the engines rather than replacing them. He's targeting $60–70M in savings to fund that shift. Young grew up working class on Cleveland's east side, a Great Migration family – father in autos, mother working three jobs – before Princeton and a career at AOL, McAfee and Microsoft.","category":"company","datetime":1785234037,"headline":"Chris Young, Vertex CEO: A Fortt Knox Conversation"}, {"id":141035245,"url":"https://finnhub.io/api/news?id=907644a0468d61ac054182ce249d9a1ef85614834d4d246abe2d6b7ed023a0a1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"VRTX heads into its Q2 earnings release with Trikafta, Alyftrek, Casgevy and Journavx in focus as investors watch product sales and updates on ongoing pipeline studies.","category":"company","datetime":1785166320,"headline":"Vertex Gears Up to Report Q2 Earnings: What Can Investors Expect?"}, {"id":141033946,"url":"https://finnhub.io/api/news?id=75ff07118ffa82f1c08f586e8d6232740ba903a6eddbecfca1b3be71d8f36219","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.","category":"company","datetime":1785160812,"headline":"Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?"}, {"id":141010849,"url":"https://finnhub.io/api/news?id=61caf6cd2d1aa2c47d5b115b8acad8415f768278eafa34f312a4ded1833d3fa7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"VANCOUVER, British Columbia, July 24, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) announces that it has engaged MCS Market Communication Service GmbH (“MCS”) (address: Rheinpromenade 13, 0789 Monheim am Rhein; email: info@mcsmarket.de) to provide marketing services for an expected term of 3 months, commencing July 27, 2026, provided that the term of the marketing services may be extended or shortened at the discretion of management","category":"company","datetime":1784926800,"headline":"Vortex Energy Corp. Announces Marketing Program"}, {"id":140994788,"url":"https://finnhub.io/api/news?id=531056513eb02609f4a4938c9a9d323461a433a76b4cbd553c5d298c12047e7a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"With its first drug on the market and a pipeline full of catalysts, the company asks investors to weigh a powerful growth story against an elevated valuation and a history of volatility.","category":"company","datetime":1784818856,"headline":"Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company?"}, {"id":140992567,"url":"https://finnhub.io/api/news?id=f03ef675567d5108e942c33fea0af0f892d3babe234791d60ea6de7bc0d32119","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, which has supported the industry’s returns lately - over the past six months, healthcare stocks have gained 10%, nearly mirroring the S&P 500.","category":"company","datetime":1784802168,"headline":"3 Healthcare Stocks with Competitive Advantages"}, {"id":140989341,"url":"https://finnhub.io/api/news?id=9a4acf17d85cd62640b1ef99d26433eb4843ddd26ea54db4439b95b95e06927d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $472.57, marking a -1.96% move from the previous day.","category":"company","datetime":1784757004,"headline":"Vertex Pharmaceuticals (VRTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know"}, {"id":140988043,"url":"https://finnhub.io/api/news?id=4e6b58aa0243c4cf3ed6fa01c255ff8093c21f5501c6043b24f8e69611512bd7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Analysts expect new details on the lead-up to the deal “are likely to reignite” investor scrutiny that Vertex overpaid in what’s poised to be its largest-ever transaction.","category":"company","datetime":1784738880,"headline":"Vertex was sole bidder in high-premium Crinetics acquisition"}, {"id":140975311,"url":"https://finnhub.io/api/news?id=25ea968d0976819831cb67877ca7d310eb561e52b6e6376eb848ef60154d12c1","image":"https://cdn.benzinga.com/files/images/story/2026/07/21/Russell-2000-Index--Text-On-Notebook-Wit.jpg?width=2048&height=1536","source":"Benzinga","related":"VRTX","summary":"Seven small-cap stocks have surged as much as 123% in early July on buyouts, FDA developments, refinancing deals and short squeezes.","category":"company","datetime":1784649148,"headline":"These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why"}, {"id":140970568,"url":"https://finnhub.io/api/news?id=17b796c52376fef7d61ed6758f543a5b5122e8be4093a5b173e2914f2be71336","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"(American News Group News Commentary) For the millions of people who manage diabetes with daily insulin injections, the holy grail has always been the same: a therapy that senses blood sugar and releases the right amount of insulin on its own, the way a healthy pancreas does. A growing group of biotech companies is chasing that goal with cell-based therapies, and this week one small player took a concrete step toward making its version real.","category":"company","datetime":1784638800,"headline":"A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up"}, {"id":140970448,"url":"https://finnhub.io/api/news?id=4a0e1ac981bb5a7f38fee8acbaf68052de3d913022a498bdaffa2648573b9719","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"(Bloomberg) -- The biotechnology sector is stealing the US IPO market thunder from artificial intelligence-related listings, delivering standout returns as bankers line up a steady stream of summer debuts.Most Read from BloombergYemen’s Houthis to Impose Maritime Blockade on Saudi ArabiaChina AI Sensation Moonshot’s Gamble on Big Models Pays OffTrump Vows 50% Tariff on Canadian Goods Using Depression-Era LawMoonshot’s Kimi K3 May Be More About Memory Than ComputeUS Strikes Iran in Escalating Cam","category":"company","datetime":1784637325,"headline":"Biotech IPO Gains Crush AI Listings With Standout 55% Return"}, {"id":140969778,"url":"https://finnhub.io/api/news?id=27a8f9b4c11fb3341b7a9d59fe254f0b38844816434279378c40ce04a712ba81","image":"https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp","source":"ChartMill","related":"VRTX","summary":"Vertex Pharmaceuticals offers affordable growth with strong double-digit earnings and revenue expansion, zero debt, and a P/E below the S&P 500 average—trading at a deep discount to biotech peers.","category":"company","datetime":1784636429,"headline":"Vertex Pharmaceuticals (NASDAQ:VRTX): An Affordable Growth Stock Balancing Strong Fundamentals With Reasonable Valuation"}, {"id":140966272,"url":"https://finnhub.io/api/news?id=873f6ef6e8863740f15f5ee5dac12b06b5a4bce91785b0cbcd6cc716a92c8621","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $480.5, denoting a -1.06% move from the preceding trading day.","category":"company","datetime":1784584806,"headline":"Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today"}, {"id":140958171,"url":"https://finnhub.io/api/news?id=92d5092f112f44af843f3884d48faf9004532046bab42282250b2a22dc512f2d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Earlier this month, the FDA expanded approval of Vertex Pharmaceuticals’ gene therapy Casgevy (exagamglogene autotemcel) to children aged 2 and older with sickle cell disease and transfusion-dependent thalassemia, following strong efficacy signals in two small pediatric trials. This milestone meaningfully widens access to a first-in-class gene therapy for very young patients, reinforcing Vertex’s role in genetic medicines beyond its cystic fibrosis core. We’ll examine how broadening...","category":"company","datetime":1784538570,"headline":"How FDA’s Pediatric Expansion of Casgevy at Vertex Pharmaceuticals (VRTX) Has Changed Its Investment Story"}, {"id":140957169,"url":"https://finnhub.io/api/news?id=eff47664a09c223d3bd87244ea256a86d7edb50f9be4a91c0183fbb81ead926f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals' gene therapy exagamglogene autotemcel (Casgevy) has received expanded FDA approval. The approval now includes children as young as 2 years old with sickle cell disease or transfusion-dependent thalassemia. This decision broadens treatment options for a pediatric group with limited alternatives. For investors watching NasdaqGS:VRTX, the expanded approval highlights how Vertex Pharmaceuticals is building out its rare disease franchise around genetic medicines. The...","category":"company","datetime":1784524037,"headline":"Vertex Pharmaceuticals (VRTX) Wins FDA Nod To Treat Children As Young As 2"}, {"id":140956306,"url":"https://finnhub.io/api/news?id=83d73f2ff98d0ae97212a4f0871c30b3aa6f32ee58d242286e4e3a28433d61cd","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"The biotech's diversification efforts continue.","category":"company","datetime":1784505900,"headline":"Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching"}, {"id":140921040,"url":"https://finnhub.io/api/news?id=b38cca16ff3fdab553b9d5e5467ff26d8301f3f124e2c0c76e4b155de1bc8e82","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like profitability concerns, rising costs, or shifts in market trends.","category":"company","datetime":1784214322,"headline":"1 Nasdaq 100 Stock to Keep an Eye On and 2 We Question"}, {"id":140919919,"url":"https://finnhub.io/api/news?id=ac38e40815783f8ec5171d72b4c86aa0d5496672e10888f4bb0f5347b866864d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Get paid a guaranteed income on your Vertex shares today, which you keep no matter what, for agreeing to sell them at a higher price if the stock keeps climbing.","category":"company","datetime":1784207177,"headline":"Collect 9.8% On VRTX Stock Now, And Still Keep 15% Of Upside"}, {"id":140921115,"url":"https://finnhub.io/api/news?id=c30edaca5af32f3105a0567a5af374e6b5c51828db4fe6b490b1d148d2a5a47e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.","category":"company","datetime":1784206803,"headline":"Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It"}, {"id":140919920,"url":"https://finnhub.io/api/news?id=22f201450e4146a22e8d333752623c653c83dfc64ed8ec26c95bd36b95ee5206","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Technical review to strengthen subsurface model and guide next phase of developmentVANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to provide a corporate update on the ongoing technical study being completed by Lonquist Field Service (Canada), ULC (“Lonquist”) at the Company’s Robinsons River Salt Project (the “Project”), located approximately 35 kilometres south of Stephenville, Newfoun","category":"company","datetime":1784203200,"headline":"Vortex Energy Provides Corporate Update on Robinsons River Salt Project Technical Study"}, {"id":140918684,"url":"https://finnhub.io/api/news?id=c5cd568c38c82229699ecfeff65d5f3e8af22b1b318f0d131623d8f2582c384d","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2190808580/image_2190808580.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"VRTX","summary":"The curing sickle cell through gene therapy story is a long way from being written. But it’s for sure that it has not gone like some of its participants have wanted it to. Read more here...","category":"company","datetime":1784187000,"headline":"The Battle For Sickle Cell"}, {"id":140925193,"url":"https://finnhub.io/api/news?id=a1e97ddb4115cd5f851ad1b2dcb8625c247944437da76f2f5a37275be9ebfa7d","image":"https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_4.jpg?width=2048&height=1536","source":"Benzinga","related":"VRTX","summary":"Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 7.55% on an annualized basis producing an average annual return of 19.41%. Currently, Vertex Pharmaceuticals has a market","category":"company","datetime":1784135733,"headline":"$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today"}, {"id":140911439,"url":"https://finnhub.io/api/news?id=a706d9b34a32e9ee4e72c8bb0e5c93ecc188bc198255ecbd232c037a410bf5d7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"An ETF's label tells you the category, but the real story is always in the portfolio's actual shape.","category":"company","datetime":1784132585,"headline":"IBB ETF Holds Fewer Bets Than You Think"}, {"id":140909807,"url":"https://finnhub.io/api/news?id=894eb83bae3b7701338821979d336d28e14b5029ab6a7dc8a0330d7df2b3d9fb","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the 10 affordable biotech stocks to buy right now. On July 6, Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) and Vertex Pharmaceuticals announced that both companies have agreed to a definitive agreement, according to which Vertex will acquire Crinetics Pharmaceuticals. The deal is priced at $85 a share in cash consideration, […]","category":"company","datetime":1784124103,"headline":"Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal"}, {"id":140897048,"url":"https://finnhub.io/api/news?id=8fd522063fde651778f609334b93b87ac175d51b99792eac01e61e5ec2bdd003","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex's $10 billion acquisition may have spooked investors, given how rich it appeared to be.","category":"company","datetime":1784031600,"headline":"Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals"}, {"id":140892612,"url":"https://finnhub.io/api/news?id=3d6b8baa9a83aa76e7cac3b939b0b62322f2dc6cbddd01beda9acf03fcca2fe6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals (VRTX) reached $480.25 at the closing of the latest trading day, reflecting a -1.06% change compared to its last close.","category":"company","datetime":1783980006,"headline":"Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors"}, {"id":140891369,"url":"https://finnhub.io/api/news?id=cd9d911d1d1ddc04410b592e494aed229ad87f0921faa2794983c8582dbd1465","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, July 13, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) announces that it has closed its previously announced non-brokered private placement financing (the “Private Placement”). The Company issued an aggregate of 5,000,000 units of the Company (the “Units”) at a price of $0.30 per Unit for gross proceeds of $","category":"company","datetime":1783979160,"headline":"Vortex Energy Corp. Announces Closing of LIFE Offering"}, {"id":140889916,"url":"https://finnhub.io/api/news?id=e8a7de07cc162dea1ae6251224928f62de69baad025c1e8b989c861cc24f2a14","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals recently announced its largest-ever acquisition.","category":"company","datetime":1783968427,"headline":"Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?"}, {"id":140891092,"url":"https://finnhub.io/api/news?id=7de8e9d2f4590eeb57173c106d795ec9e57e4287831ea47e3a3f0eb5dc45f49e","image":"","source":"Benzinga","related":"VRTX","summary":"UBS analyst Michael Yee maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $545 to $585.","category":"company","datetime":1783952283,"headline":"UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $585"}, {"id":140891370,"url":"https://finnhub.io/api/news?id=03bcc91f3ed155fa3ddcb91bbc261b06b7a6a3b1554a720faace2ae6851096e3","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.","category":"company","datetime":1783951045,"headline":"What to Expect From Vertex Pharmaceuticals' Next Quarterly Earnings Report"}, {"id":140891093,"url":"https://finnhub.io/api/news?id=fd93aff66889dc24055c8b99639e5acc340f6629383543951e341c24f0b63207","image":"","source":"Benzinga","related":"VRTX","summary":"Truist Securities analyst Danielle Brill maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $542 to $560.","category":"company","datetime":1783945862,"headline":"Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $560"}, {"id":140874823,"url":"https://finnhub.io/api/news?id=74393636e844e518614a2f2bbc4b00f4b95cda8bb29e624da6373305bfa8aab5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals (NasdaqGS:VRTX) received expanded FDA approval for CASGEVY, extending use to children as young as 2 years with sickle cell disease and beta thalassemia. The company also signed a Letter of Intent with Canadian national payers that outlines commercial access terms for ALYFTREK, its next generation cystic fibrosis therapy. These updates arrive as Vertex Pharmaceuticals trades around $485.39 and remains closely watched after a 140.0% return over the past 5 years and a...","category":"company","datetime":1783826346,"headline":"Vertex (VRTX) Wins FDA Expansion For CASGEVY And Advances ALYFTREK In Canada"}, {"id":140873536,"url":"https://finnhub.io/api/news?id=e9086ad552f75890511f4f50816a1086a025168d4d5bcc85a6530a23c82a78c6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Vertex Pharmaceuticals (NASDAQ:VRTX) said it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, a transaction Vertex executives described as a strategic expansion into specialty endocrinology. On a conference call announcing the deal, Vertex CEO","category":"company","datetime":1783803729,"headline":"Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse"}, {"id":140866271,"url":"https://finnhub.io/api/news?id=3474024df282bf83c2487827c06844fbdf81b888de20d743220ca244b809d07e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"It's been a volatile year for the company, but don't let that scare you away.","category":"company","datetime":1783718400,"headline":"Is This Biotech Stock a Buy Near Its 52-Week High?"}, {"id":140865211,"url":"https://finnhub.io/api/news?id=c9b07089322e23d06265dae52c2992c333bdcda8fef02ebe98f458bef38d5d1f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"It is getting acquired by a larger firm in the sector.","category":"company","datetime":1783711352,"headline":"Why This Pharmaceutical Stock Jumped Close to 100% This Week"}, {"id":140861703,"url":"https://finnhub.io/api/news?id=af70857a11cc855d135aa4dbacdfb09561eefbc7830e6114b9d2980a93d0ad6f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.","category":"company","datetime":1783686601,"headline":"If You Invested $1000 in Vertex Pharmaceuticals a Decade Ago, This is How Much It'd Be Worth Now"}, {"id":140861704,"url":"https://finnhub.io/api/news?id=261335ddb3a4405ad09573cc88858404a83f044cb91dc30fe6fb403e911b1373","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"With its lead drug driving rapid growth and three more on deck, the biotech is betting it can outrun future competition and a history of volatility.","category":"company","datetime":1783685653,"headline":"Beyond The Breakout Drug: Is BridgeBio Pharma Stock A Buy On Its Next Act?"}, {"id":140860831,"url":"https://finnhub.io/api/news?id=70bace5e39146e0e64ac0773b15c6a491cc88cb329eb3be14cd2305070834fcd","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"A look at the company's history of deep drawdowns shows the real risk shareholders are carrying today.","category":"company","datetime":1783683335,"headline":"The Long Climb Back For Ionis Stock"}, {"id":140859839,"url":"https://finnhub.io/api/news?id=cdd9c810230d73c852b260a9d4bceec99d4b0eebc8f9e6457c65267d2e0ad5c7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"VRTX","summary":"Additional blockbuster drugs may be on the horizon.","category":"company","datetime":1783671900,"headline":"Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy?"}
data_source finnhub_news_keyword_model
article_count 8
negative_hits 0
positive_hits 4
recomputed_at_score true
sentiment_score_raw 1.2
source_article_count 91
discarded_article_count 66
sentimentPoints 6

Dimension contribution

Dimension Raw Max Norm % Contrib
基本面 3.8 5/110 76% 3.8
資金流 10 20/110 50% 10
市場環境 7.2 15/110 48% 7.2
催化劑 2 20/110 10% 2
風險管理 7.2 10/110 72% 7.2
技術信號 23.6 30/110 78.67% 23.6
情緒分析 6 10/110 60% 6

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 11/50
ret_5d 0.0398
max_score 50
max_total 50
raw_total 11
vcp_bonus 0
vol_ratio 0.7409
ret_points 8
vol_points 0
range_ratio 1.1976
volat_points 0
day_range_pct 0.0308
model_version cursor_18_27_news_v2_160
available_bars 30
breakout_points 0
partial_history false
pullback_points 3
breakout_vol_bonus 0
first_breakout_20d false
return_window_days 5
first_breakout_bonus 0
breakout_quality_points 0

Risk management

level Medium
reason risk management score >= 6.5/10

position

score 1.6

details

atrPct 2.6724
turnoverUsdM 492.2999
liquidityPoints 0.6
volatilityPoints 1
rrPoints 1.8

stopLevels

symbol US.VRTX
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 469.5558

strength_details

ma_score 2
atr_score 2
rsi_score 3
macd_score 3
volume_score 1
market_adjustment 1
risk_reward_ratio 1.7
stop_loss_percent 5.3
take_profit_price 539.8184
target_multiplier 2.2
technical_strength 2.25
take_profit_percent 8.8
positionPoints 1.6
stopLossPoints 1.8

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.6464
stopLossPercent 5.3449
diversificationPoints 2

Calculation audit log

基本面分析總分: 3.8/5分
資金流分析總分: 10/20分
市場環境分析總分: 7.2/15分
催化劑分析: 2/20分
風險管理總分: 7.2/10分
技術信號分析總分: 23.6/30分
情緒分析: 6/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx
value 100
atr
atr 13.2571
rule ATR / current price; lower volatility scores higher
score 6
atr_pct 2.67
cci
rule Cursor_18.24 CCI bands
level 超買或超賣風險
score 2
value 159.68
cmf
rule Cursor_18.24 CMF bands
level 派發
score 2
value -0.0535
kdj
d 56.29
j 95.72
k 69.43
rule Cursor_18.24 K/D cross
score 6
signal 強金叉
mfi
rule Cursor_18.24 MFI bands
level 平衡
score 6
value 53.31
obv
rule Cursor_18.24 recent_slope vs previous_slope
score 4
trend 弱勢
value 14020300
recentSlope -8130
previousSlope 280890
rsi
value 60.33
sar
rule Cursor_18.24 Parabolic SAR
score 8
trend 上升
value 469.2697
position SAR喺價下
distancePct 5.4
previousTrend 上升
ma50
value 473.1562
macd
macd 1.962
trend 強烈看漲
signal 1.6492
histogram 0.3128
vwap
rule Cursor_18.24 VWAP 20D consecutive close
score 8
value 480.9734
position 連續3日>VWAP
consecutiveAbove 3
volume
rule Cursor_18.24 volume ratio
level 空升
ratio 0.75
score 2
avgVolume 1317605
currentVolume 992400
derived
ma20 480.836
ma50 473.1562
prevClose 484.03
avgVolume10 1391570
avgVolume20 1317605
changePercent 2.49
avgVolumeForScore 1317605
ma_cross
ma20 480.836
ma50 473.1562
rule Cursor_18.24 MA20/MA50 cross
cross 接近
score 6
prevMa20 480.302
prevMa50 471.9792
spreadPct 1.62
isVolumeBreakout false
bollinger
lower 468.9396
upper 492.7324
position 上半部
rsi_short
value 68.94
macd_short
macd 0
trend 中性
signal 0
histogram 0
volume_ratio
ratio 0.75

Raw calculation JSON

 
{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.6,
      "details": {
        "atrPct": 2.672425224853394,
        "turnoverUsdM": 492.2998749468,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.8,
    "stopLevels": {
      "symbol": "US.VRTX",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 469.5558,
      "strength_details": {
        "ma_score": 2,
        "atr_score": 2,
        "rsi_score": 3,
        "macd_score": 3,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.7,
      "stop_loss_percent": 5.3,
      "take_profit_price": 539.8184,
      "target_multiplier": 2.2,
      "technical_strength": 2.25,
      "take_profit_percent": 8.8
    },
    "positionPoints": 1.6,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.646444569928567,
    "stopLossPercent": 5.344850449706788,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 70.8,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 59.8,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 11
  },
  "market": {
    "ma20": 480.836,
    "ma50": 473.1562,
    "close": 496.07,
    "prevClose": 484.03,
    "avgVolume20": 1317605,
    "volumeRatio": 0.75,
    "changePercent": 2.49
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 11,
    "details": {
      "ret_5d": 0.03976104926092949,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 11,
      "vcp_bonus": 0,
      "vol_ratio": 0.7408762257417908,
      "ret_points": 8,
      "vol_points": 0,
      "range_ratio": 1.197619351200618,
      "volat_points": 0,
      "day_range_pct": 0.030842380680354265,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 70.8,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 3.8,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 76,
        "contribution": 3.8
      },
      {
        "raw": 10,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 50,
        "contribution": 10
      },
      {
        "raw": 7.2,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 48,
        "contribution": 7.2
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.2,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 72,
        "contribution": 7.2
      },
      {
        "raw": 23.6,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 78.67,
        "contribution": 23.6
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "觀望",
    "result": 59.8,
    "details": [
      "基本面分析總分: 3.8/5分",
      "資金流分析總分: 10/20分",
      "市場環境分析總分: 7.2/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.2/10分",
      "技術信號分析總分: 23.6/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 3.8,
      "資金流": 10,
      "市場環境": 7.2,
      "情緒分析": 6,
      "技術信號": 23.6,
      "風險管理": 7.2
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "良好",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0.75,
          "debtPoints": 0.5,
          "marginPoints": 0.75,
          "turnoverUsdM": 492.2998749468,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 2.4,
          "obvPoints": 1.6,
          "vwapPoints": 3.2,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.VRTX",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 3.4,
            "details": {
              "qqq": {
                "ma20": 700.3394962,
                "ma50": 714.56740032,
                "name": "QQQ",
                "close": 723.030029,
                "points": 1.4
              },
              "spy": {
                "ma20": 750.17250065,
                "ma50": 747.18900276,
                "name": "SPY",
                "close": 773.26001,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.672425224853394,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 0,
          "marketTrendPoints": 3.4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 4,
              "sentimentScoreRaw": 1.2
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141111809,
                "url": "https://finnhub.io/api/news?id=c75088a93dadcf9e8e98257af8b682dac1d13336bde4d21c44821d1d977692b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex's Q2 earnings miss estimates, but revenues beat. It lifts its 2026 sales outlook, and sees growing contributions from newer products.",
                "category": "company",
                "datetime": 1785855420,
                "headline": "VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised"
              },
              {
                "id": 141110156,
                "url": "https://finnhub.io/api/news?id=f3baecf2b44e7c92410111d5cff7381e367457398aba185e3d320a8c7d034127",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex raises its 2026 revenue outlook as CF growth, newer products and a near-term renal launch strengthen its diversification push.",
                "category": "company",
                "datetime": 1785852000,
                "headline": "VRTX Q2 Earnings Call Highlights Launch Momentum & Higher Outlook"
              },
              {
                "id": 141107841,
                "url": "https://finnhub.io/api/news?id=21c2ae1e0954cdae5c7b9195cab02ce3174708240085a53081522118a8c97864",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NasdaqGS:VRTX) has agreed to acquire Crinetics Pharmaceuticals in a deal expected to close in the third quarter of 2026. The transaction is designed to broaden Vertex's reach in biotech and add new disease areas beyond its core cystic fibrosis franchise. Investors are watching for the potential impact on Vertex's drug pipeline and competitive position as the companies work toward closing. Vertex Pharmaceuticals enters this deal with a sizeable track record in cystic...",
                "category": "company",
                "datetime": 1785841838,
                "headline": "Vertex (VRTX) Buys Crinetics To Push Beyond Cystic Fibrosis"
              },
              {
                "id": 141106171,
                "url": "https://finnhub.io/api/news?id=dd56684479086b09a9c08b3176c470d1855c316ea8c11773c551232e8fcd3c7d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex raises full-year 2026 revenue guidance to $13.1-$13.2 billion as CASGEVY and JOURNAVX show strong sequential growth, while advancing a robust pipeline and strategic Crinetics acquisition.",
                "category": "company",
                "datetime": 1785820106,
                "headline": "Vertex Pharmaceuticals Inc (VRTX) (Q2 2026) Earnings Call Highlights: Revenue Surges 12% to $3. ..."
              },
              {
                "id": 141105354,
                "url": "https://finnhub.io/api/news?id=7e00387653f41c77398a88e148bbf63751fee590b653e4f81ecdb065f240f8c5",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call August 3, 2026 4:30 PM EDTCompany ParticipantsSusie Lisa - Senior Vice President of...",
                "category": "company",
                "datetime": 1785798598,
                "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141104290,
                "url": "https://finnhub.io/api/news?id=2c85fd6651e8a37c93bd116754644b8c8fdc608ac20c6dd3606025ce523510da",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
                "category": "company",
                "datetime": 1785792601,
                "headline": "Vertex (VRTX) Reports Q2 Earnings: What Key Metrics Have to Say"
              },
              {
                "id": 141104291,
                "url": "https://finnhub.io/api/news?id=3312282938d1eebf9e011d1fbb4c0cede96428eca208a72aa3620cc06e6c5b8a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex (VRTX) delivered earnings and revenue surprises of -1.25% and +3.32%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785792003,
                "headline": "Vertex Pharmaceuticals (VRTX) Q2 Earnings Lag Estimates"
              },
              {
                "id": 141103108,
                "url": "https://finnhub.io/api/news?id=2107a32523531702676a61163a0ada3a64e71398d16b7a18148ca98956bb5707",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) announced better-than-expected revenue in Q2 CY2026, with sales up 12.5% year on year to $3.33 billion. The company’s full-year revenue guidance of $13.15 billion at the midpoint came in 0.7% above analysts’ estimates. Its non-GAAP profit of $4.73 per share was in line with analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1785789407,
                "headline": "Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q2 CY2026 Sales Expectations, Full-Year Outlook Slightly Exceeds Expectations"
              }
            ],
            "raw_source": [
              {
                "id": 141163533,
                "url": "https://finnhub.io/api/news?id=3b7a86f6ceb88fe11df34224171d2e64d74b5e8b7d5f7a718f923ea58fe91d9c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1160013511/image_1160013511.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "Tweedy Browne’s Q2 2026 13F: $1.32B portfolio, top holdings & new Zoetis stake, plus trims/exits and concentration insights—read now.",
                "category": "company",
                "datetime": 1786229949,
                "headline": "Tracking Tweedy Browne Portfolio - Q2 2026 Update"
              },
              {
                "id": 141150935,
                "url": "https://finnhub.io/api/news?id=f30205fda5e3671faae31aaf11b68289bc37bc3003af8d9080eae74361b10542",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "This risk is weighing on the stock.",
                "category": "company",
                "datetime": 1786126800,
                "headline": "Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire?"
              },
              {
                "id": 141148212,
                "url": "https://finnhub.io/api/news?id=f1429036e90b90226a0f1548de75810532846ed909768a41040c55c430c961bf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Management has just raised the peak-sales estimate, and a large slice of it belongs to a drug still running Phase III trials.",
                "category": "company",
                "datetime": 1786117197,
                "headline": "What Insmed Stock's Premium Is Actually Buying"
              },
              {
                "id": 141135446,
                "url": "https://finnhub.io/api/news?id=fd1d07072af0353df58d8c6462fe44867241410e634aa7fe7a706972fa6edc43",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "IONQ posts a wider-than-expected Q2 loss but tops revenue estimates, raises its 2026 revenue outlook and sees shares rise after the results.",
                "category": "company",
                "datetime": 1786027140,
                "headline": "IONQ Q2 Earnings Miss Estimates, Revenues Beat, Stock Rises"
              },
              {
                "id": 141134178,
                "url": "https://finnhub.io/api/news?id=d3341145831fa1164ba72987649fc3f9cde6dfde5df1d47e24be44aed8cc7b65",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Study confirms western salt structure, identifies an eastern exploration target and establishes a staged technical pathway for further evaluationVANCOUVER, British Columbia, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce, further to its news release dated July 16, 2026, that it has received the final technical study prepared by Lonquist Field Service (Canada), ULC (“Lonquist”) for the Company’s Robinson",
                "category": "company",
                "datetime": 1786017600,
                "headline": "Vortex Energy Receives Final Technical Study Results for the Robinsons River Salt Project"
              },
              {
                "id": 141131676,
                "url": "https://finnhub.io/api/news?id=42acecf7bad1baa7ec04cb7ac59418a1c1004daf4cddd4cce6da65363ef901db",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "AbCellera Biologics Inc (ABCL) advances ABCL-635 with early phase 2 completion and secures over $110 million in new T-cell engager deals, despite a wider net loss and revenue decline.",
                "category": "company",
                "datetime": 1785992501,
                "headline": "AbCellera Biologics Inc (ABCL) (Q2 2026) Earnings Call Highlights: Strong Pipeline Progress and ..."
              },
              {
                "id": 141129231,
                "url": "https://finnhub.io/api/news?id=dcdf3ce3fb9a9978376d50e78da86431a8757aa1e827d9ec985228c198f4b841",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "AbCellera Biologics (NASDAQ:ABCL) said it expects to report top-line data “very soon” from its Phase I study of ABCL635, an antibody being evaluated for moderate-to-severe vasomotor symptoms, or hot flashes, associated with menopause. President and Chief Executive Officer Dr. Carl Hansen said enrol",
                "category": "company",
                "datetime": 1785967428,
                "headline": "AbCellera Biologics Q2 Earnings Call Highlights"
              },
              {
                "id": 141128774,
                "url": "https://finnhub.io/api/news?id=2a2a2d7e0c3b0c4acf97cdb30edff26305271e2d709137a8518fb82aaeb34cfe",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Truist Securities  analyst Danielle Brill   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $560 to $565.",
                "category": "company",
                "datetime": 1785938692,
                "headline": "Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $565"
              },
              {
                "id": 141120403,
                "url": "https://finnhub.io/api/news?id=f62b2e86c4216e2bda2377255cef430a7f277cbdefbb4b3b2c17c9278e69b758",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "-- Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- -- Company to report ELEVATE-45-201 Cohort 1 data in October 2026 -- -- ELEVATE-45-201 Cohort 2 dosing ongoing at the increased dose of 10 mg/kg with data expected in H1 2027 -- -- Vertex to report VX-670 Phase 1/2 data in people living with DM1 in H2 2026 -- BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc",
                "category": "company",
                "datetime": 1785927600,
                "headline": "Entrada Therapeutics Reports Second Quarter 2026 Financial Results"
              },
              {
                "id": 141121678,
                "url": "https://finnhub.io/api/news?id=5248f37b608df4175afdacfec21505a887b9d7e62e088904934c0a4a097c8b4d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2288169175/image_2288169175.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "CRISPR Therapeutics (CRSP) remains a Strong Buy, supported by robust CASGEVY sales growth and pipeline expansion.",
                "category": "company",
                "datetime": 1785924544,
                "headline": "CRISPR: \"Strong Buy\" CASGEVY Sales Growth And In Vivo Expansion With CTX310"
              },
              {
                "id": 141128775,
                "url": "https://finnhub.io/api/news?id=4a00fc07417e00a900782dede2c3227b5bb2ffd5494048eb5e0a007a66482462",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Barclays  analyst Eliana Merle   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $615 to $617.",
                "category": "company",
                "datetime": 1785922255,
                "headline": "Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $617"
              },
              {
                "id": 141111807,
                "url": "https://finnhub.io/api/news?id=e47001faa115166263a442f28230abdba42b95d19b8edb04e4fd9ecec1553469",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) remains well positioned heading into the second half of 2026 as severa",
                "category": "company",
                "datetime": 1785863115,
                "headline": "Vertex Pharmaceuticals Seen Well Positioned Ahead of Pipeline Catalysts, UBS Says"
              },
              {
                "id": 141111808,
                "url": "https://finnhub.io/api/news?id=1779ffa16d4cf28c1b259ac324be9f15ee814476b807b5bf97951a8231ca3e17",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) reported a solid Q2 and raised its outlook, highlighting the strength",
                "category": "company",
                "datetime": 1785859337,
                "headline": "Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says"
              },
              {
                "id": 141110155,
                "url": "https://finnhub.io/api/news?id=ab934a24772cacbc2444176e33fe2e26a3432801ece501642cda46733319fe6f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex stock regained its footing Tuesday, rising on a strong second-quarter report and amid heightened expectations for its kidney disease treatment.",
                "category": "company",
                "datetime": 1785855630,
                "headline": "How Vertex Regained Its Footing On A Competitor's Bullish Report"
              },
              {
                "id": 141111809,
                "url": "https://finnhub.io/api/news?id=c75088a93dadcf9e8e98257af8b682dac1d13336bde4d21c44821d1d977692b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex's Q2 earnings miss estimates, but revenues beat. It lifts its 2026 sales outlook, and sees growing contributions from newer products.",
                "category": "company",
                "datetime": 1785855420,
                "headline": "VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised"
              },
              {
                "id": 141110509,
                "url": "https://finnhub.io/api/news?id=f6f657f73b56d365c3988923bf6a3d9124e87491e39b6391d0a32defb58016c3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "CRSP reports a narrower-than-expected Q2 loss. Revenues beat estimates as Casgevy sales surge across global markets and clinical programs advance.",
                "category": "company",
                "datetime": 1785855360,
                "headline": "CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates"
              },
              {
                "id": 141110156,
                "url": "https://finnhub.io/api/news?id=f3baecf2b44e7c92410111d5cff7381e367457398aba185e3d320a8c7d034127",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex raises its 2026 revenue outlook as CF growth, newer products and a near-term renal launch strengthen its diversification push.",
                "category": "company",
                "datetime": 1785852000,
                "headline": "VRTX Q2 Earnings Call Highlights Launch Momentum & Higher Outlook"
              },
              {
                "id": 141120404,
                "url": "https://finnhub.io/api/news?id=536ca1939192aa75d5e6bab55534f6b569982fd11bc66824814b4cc31c74a4a9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Moby summary of Vertex Pharmaceuticals Incorporated's Q2 2026 earnings call",
                "category": "company",
                "datetime": 1785846600,
                "headline": "Vertex Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary"
              },
              {
                "id": 141128776,
                "url": "https://finnhub.io/api/news?id=a0e8acf95ce40887b103881fce5237ca4516cca5aecd8d5b7c448a54203438f4",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "TD Cowen  analyst Phil Nadeau   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $525 to $550.",
                "category": "company",
                "datetime": 1785846489,
                "headline": "TD Cowen Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $550"
              },
              {
                "id": 141111811,
                "url": "https://finnhub.io/api/news?id=e0958b66343c41ec1dc90eccdc735fecb25accfdb235add8df6547d345ab61de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Despite another strong earnings report, analysts warned that upcoming cystic fibrosis data from Sionna Therapeutics \"looms large\" over Vertex.",
                "category": "company",
                "datetime": 1785845940,
                "headline": "Vertex’s biggest overhang: a rival 50 times smaller"
              },
              {
                "id": 141107841,
                "url": "https://finnhub.io/api/news?id=21c2ae1e0954cdae5c7b9195cab02ce3174708240085a53081522118a8c97864",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NasdaqGS:VRTX) has agreed to acquire Crinetics Pharmaceuticals in a deal expected to close in the third quarter of 2026. The transaction is designed to broaden Vertex's reach in biotech and add new disease areas beyond its core cystic fibrosis franchise. Investors are watching for the potential impact on Vertex's drug pipeline and competitive position as the companies work toward closing. Vertex Pharmaceuticals enters this deal with a sizeable track record in cystic...",
                "category": "company",
                "datetime": 1785841838,
                "headline": "Vertex (VRTX) Buys Crinetics To Push Beyond Cystic Fibrosis"
              },
              {
                "id": 141107179,
                "url": "https://finnhub.io/api/news?id=06027c260ce9de9f61eb87edc3fd3f074dda0e76b30bcca2da7b0e57104fa68b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Crinetics Pharmaceuticals stock has delivered very strong gains over the past few years, yet the current valuation checks point to a market price that leans expensive rather than clearly cheap. Crinetics Pharmaceuticals has returned about 384% over the past 3 years, which puts recent enthusiasm for the stock firmly in focus for anyone thinking about upside from here. Vertex Pharmaceuticals' agreement to acquire Crinetics and the regulatory progress for atumelnant can support high...",
                "category": "company",
                "datetime": 1785834837,
                "headline": "Crinetics Pharmaceuticals (CRNX) Stock Looks Pricey As Buyout News Lands"
              },
              {
                "id": 141110584,
                "url": "https://finnhub.io/api/news?id=83f00ed155351fa091931ebd6f19d490a2410a74beb0fca26cc0781a757d8552",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Cantor Fitzgerald  analyst Carter Gould   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $590 to $595.",
                "category": "company",
                "datetime": 1785831893,
                "headline": "Cantor Fitzgerald Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $595"
              },
              {
                "id": 141107416,
                "url": "https://finnhub.io/api/news?id=79c24c254426f5197e92c42652e8d662216c9656ed34db5290a7b518a70f7c0b",
                "image": "",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "",
                "category": "company",
                "datetime": 1785826663,
                "headline": "Vertex Pharmaceuticals: A Transition Year Into A Multi-Franchise Growth Story"
              },
              {
                "id": 141106171,
                "url": "https://finnhub.io/api/news?id=dd56684479086b09a9c08b3176c470d1855c316ea8c11773c551232e8fcd3c7d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex raises full-year 2026 revenue guidance to $13.1-$13.2 billion as CASGEVY and JOURNAVX show strong sequential growth, while advancing a robust pipeline and strategic Crinetics acquisition.",
                "category": "company",
                "datetime": 1785820106,
                "headline": "Vertex Pharmaceuticals Inc (VRTX) (Q2 2026) Earnings Call Highlights: Revenue Surges 12% to $3. ..."
              },
              {
                "id": 141105354,
                "url": "https://finnhub.io/api/news?id=7e00387653f41c77398a88e148bbf63751fee590b653e4f81ecdb065f240f8c5",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call August 3, 2026 4:30 PM EDTCompany ParticipantsSusie Lisa - Senior Vice President of...",
                "category": "company",
                "datetime": 1785798598,
                "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141104289,
                "url": "https://finnhub.io/api/news?id=c7c1bac8a4be7e1bca887af4abc9e92a06d03ce636155d166171dc8851c4e126",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NASDAQ:VRTX) reported second-quarter 2026 revenue growth of 12% year over year to $3.3 billion, driven by continued growth in its cystic fibrosis franchise and rising contributions from newer products CASGEVY and JOURNAVX. Chief Executive Officer and President Reshma Kewalra",
                "category": "company",
                "datetime": 1785798229,
                "headline": "Vertex Pharmaceuticals Q2 Earnings Call Highlights"
              },
              {
                "id": 141105291,
                "url": "https://finnhub.io/api/news?id=cd71711e25cb163c9f05f483851c9f5b6b7eb81c55fa46d409773ec5676efefb",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "2026-08-03. The following slide deck was published by Vertex Pharmaceuticals Incorporated in conjunction with their 2026 Q2 earnings call.",
                "category": "company",
                "datetime": 1785798079,
                "headline": "Vertex Pharmaceuticals Incorporated 2026 Q2 - Results - Earnings Call Presentation"
              },
              {
                "id": 141104290,
                "url": "https://finnhub.io/api/news?id=2c85fd6651e8a37c93bd116754644b8c8fdc608ac20c6dd3606025ce523510da",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
                "category": "company",
                "datetime": 1785792601,
                "headline": "Vertex (VRTX) Reports Q2 Earnings: What Key Metrics Have to Say"
              },
              {
                "id": 141104291,
                "url": "https://finnhub.io/api/news?id=3312282938d1eebf9e011d1fbb4c0cede96428eca208a72aa3620cc06e6c5b8a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex (VRTX) delivered earnings and revenue surprises of -1.25% and +3.32%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785792003,
                "headline": "Vertex Pharmaceuticals (VRTX) Q2 Earnings Lag Estimates"
              },
              {
                "id": 141103107,
                "url": "https://finnhub.io/api/news?id=98a2abcf301231bc0d0aaead7b8926e9c78fdfcb82c76cbbb0cc6e889ba5bb06",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex stock dipped late Monday on a mixed second-quarter report. But the biotech giant raised its sales guidance for the year.",
                "category": "company",
                "datetime": 1785790435,
                "headline": "Vertex Raises 2026 Guidance, But Shares Dip For One Key Reason"
              },
              {
                "id": 141103108,
                "url": "https://finnhub.io/api/news?id=2107a32523531702676a61163a0ada3a64e71398d16b7a18148ca98956bb5707",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) announced better-than-expected revenue in Q2 CY2026, with sales up 12.5% year on year to $3.33 billion. The company’s full-year revenue guidance of $13.15 billion at the midpoint came in 0.7% above analysts’ estimates. Its non-GAAP profit of $4.73 per share was in line with analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1785789407,
                "headline": "Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q2 CY2026 Sales Expectations, Full-Year Outlook Slightly Exceeds Expectations"
              },
              {
                "id": 141103109,
                "url": "https://finnhub.io/api/news?id=c2b5656a468d8791f71fe09a62a59cf02bfd34ac2e88a2aafd4178787e8d1233",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Announced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net of Estimated Cash Acquired PALSONIFY® (Paltusotine) Net Product Revenue of $24.0 Million for Second-Quarter 2026 SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumor",
                "category": "company",
                "datetime": 1785787500,
                "headline": "Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update"
              },
              {
                "id": 141103110,
                "url": "https://finnhub.io/api/news?id=b906634ef71b39efd517bbbaafd8f51cefd4da9cb3e99c193c693beb458b10fa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "BOSTON, August 03, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2026, and updated its full year 2026 revenue guidance.",
                "category": "company",
                "datetime": 1785787260,
                "headline": "Vertex Reports Second Quarter 2026 Financial Results"
              },
              {
                "id": 141102404,
                "url": "https://finnhub.io/api/news?id=939a925a360f140b82437bcf1c066f9578c7f6d8d02242dd6344b422c5f7a75f",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NASDAQ:VRTX) raises FY2026 sales outlook from $12.950 billion-$13.100 billion to $13.100 billion-$13.200 billion vs $13.065 billion estimate.",
                "category": "company",
                "datetime": 1785772904,
                "headline": "Vertex Pharmaceuticals Raises FY2026 Sales Guidance from $12.950B-$13.100B to $13.100B-$13.200B vs $13.065B Est"
              },
              {
                "id": 141102405,
                "url": "https://finnhub.io/api/news?id=d851715324594ca0a83a36932e5f194d1100c4a171088992edaa84adad7f327d",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NASDAQ:VRTX) reported quarterly earnings of $4.73 per share which met the analyst consensus estimate. This is a 4.65 percent increase over earnings of $4.52 per share from the same period last",
                "category": "company",
                "datetime": 1785772886,
                "headline": "Vertex Pharmaceuticals Q2 Adj. EPS $4.73, Inline, Sales $3.334B Beat $3.232B Estimate"
              },
              {
                "id": 141101633,
                "url": "https://finnhub.io/api/news?id=210dc9eadb0f1e641b405b20d701188a86b5d7a5db961e15cc5ee67a2573203c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2231767274/image_2231767274.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "Big Tech's earnings reports laid bare a growing divide in the market's appetite for AI spending. Investors now focus on results from industrials, health care, consumer staples/discretionary.",
                "category": "company",
                "datetime": 1785766800,
                "headline": "Divided Tech, Divided Fed: Navigating AI Capex Scrutiny And Mixed Macro Signals"
              },
              {
                "id": 141098887,
                "url": "https://finnhub.io/api/news?id=48d0b35462c58b56f76fb282a857a48a7324ea7d8a8bec1032ce82a8f07a63bf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Wall Street futures pointed moderately higher pre-bell Monday after President Donald Trump, over the",
                "category": "company",
                "datetime": 1785755481,
                "headline": "Falling Oil Boosts Wall Street Pre-Bell; Asia Mixed, Europe Up"
              },
              {
                "id": 141099604,
                "url": "https://finnhub.io/api/news?id=0b813f41b7078cecf12b4aafa9a2ca131b75aa021fa9c19c50adbd14d08635cb",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/03/TysonFoods.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "U.S. stock futures up, focus on earnings from Tyson Foods, Marriott, Universal Logistics, Williams Companies, and Vertex Pharmaceuticals.",
                "category": "company",
                "datetime": 1785724052,
                "headline": "Tyson Foods, Marriott And 3 Stocks To Watch Heading Into Monday"
              },
              {
                "id": 141100201,
                "url": "https://finnhub.io/api/news?id=bad502596ada943e824fa1a41cadb663072846cc663445ce8eab7c42d8dbcca9",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/03/Fear-and-Greed.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "CNN Money Fear & Greed index improved while remaining in 'Fear' zone on Friday. Amazon up 15%, Apple down 7%.",
                "category": "company",
                "datetime": 1785723704,
                "headline": "Nasdaq Jumps 1% as Amazon Shares Surge: Investor Sentiment Improves, But Greed Index Remains in 'Fear' Zone"
              },
              {
                "id": 141091494,
                "url": "https://finnhub.io/api/news?id=fab83185dfc322c5138a32b43f26849a509ecd83026c58227dad50ddfd0cb7aa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results this Monday after the bell. Here’s what to look for.",
                "category": "company",
                "datetime": 1785645417,
                "headline": "Vertex Pharmaceuticals (VRTX) Q2 Earnings Report Preview: What To Look For"
              },
              {
                "id": 141081582,
                "url": "https://finnhub.io/api/news?id=fbee925dabbe6f460ef2b4b28c54e17bf35b8224f7677ab26790e7608838499f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "The biotech's shares have stumbled after a guidance change, and investors are weighing whether this is the moment to step in or step aside.",
                "category": "company",
                "datetime": 1785526149,
                "headline": "Is The Recent Pullback In Alnylam Stock An Opportunity Or A Trap?"
              },
              {
                "id": 141072827,
                "url": "https://finnhub.io/api/news?id=eb8ae6cb70ca7b946707a8aa4b6c4d3c77225f489baa605fe36f3ca8cc64e515",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "There are other reasons to pay attention to Viking Therapeutics.",
                "category": "company",
                "datetime": 1785451800,
                "headline": "Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target"
              },
              {
                "id": 141057143,
                "url": "https://finnhub.io/api/news?id=421d31ea5999d389b5893a796c7ed1557f77b278da24643c864ae1a8d7df7f3a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) is back in focus after AbCellera Biologics announced a collaboration to develop multispecific T cell engagers targeting autoimmune diseases and other conditions. Under the agreement, Vertex will fund the research and retain commercialization rights. See our latest analysis for Vertex Pharmaceuticals. The latest AbCellera collaboration comes as Vertex Pharmaceuticals' share price has risen 15.87% over the past 90 days and the 5 year total shareholder return sits...",
                "category": "company",
                "datetime": 1785352120,
                "headline": "Vertex Pharmaceuticals (VRTX) Expands Its Pipeline Reach, Is The Stock Fully Valued?"
              },
              {
                "id": 141055852,
                "url": "https://finnhub.io/api/news?id=af8516feb80f1c0c63d5e073b11c8faedae64310cc396f9cbb7780cbc28736e3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals has delivered a 145.1% return over the past five years, yet its current valuation picture is mixed, as a Discounted Cash Flow (DCF) intrinsic value estimate points to meaningful upside while market-based multiples look closer to fair. Over five years, Vertex Pharmaceuticals has returned 145.1%, which puts the current share price in a very different place compared with where long-term holders started. Expectations for continued cash generation from its existing...",
                "category": "company",
                "datetime": 1785341297,
                "headline": "Vertex Pharmaceuticals (VRTX) Stock Looks Like A Bargain At This Price"
              },
              {
                "id": 141054235,
                "url": "https://finnhub.io/api/news?id=ec84f806f9b56e49cb76104e77c2ce400a7ef3f40a464d06bfad72fa6a3adbbf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Evaluate the expected performance of Vertex (VRTX) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.",
                "category": "company",
                "datetime": 1785330924,
                "headline": "Vertex (VRTX) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates"
              },
              {
                "id": 141054236,
                "url": "https://finnhub.io/api/news?id=de94bed6584f5074d58e85040ba27013c8626725d9b5c8153c69645b52623247",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "The deal adds to a growing streak of partnerships involving new types of T cell engagers and gives Vertex another chance to broaden a business still reliant on cystic fibrosis medicines.",
                "category": "company",
                "datetime": 1785325200,
                "headline": "AbCellera, Vertex partner on next-gen T-cell engagers"
              },
              {
                "id": 141052195,
                "url": "https://finnhub.io/api/news?id=60bbb3013ffab29675f18d6859109afcd760881dfa67d13bb4615ac423d1506e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "VANCOUVER, British Columbia, July 29, 2026--AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions",
                "category": "company",
                "datetime": 1785322800,
                "headline": "AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions"
              },
              {
                "id": 141051677,
                "url": "https://finnhub.io/api/news?id=58593945567739718700c0a3f06ba07fe7dd080a3f1abae5a528f461dd26e8eb",
                "image": "https://www.chartmill.com/images/uploads/Strong_Growth_500_264px_webp_8f1ee6ba5b.webp",
                "source": "ChartMill",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) combines strong earnings growth, zero debt, and a consolidating technical pattern, making it a textbook breakout candidate for growth investors.",
                "category": "company",
                "datetime": 1785319828,
                "headline": "Vertex Pharmaceuticals (NASDAQ:VRTX): Strong Growth and Textbooks Technical Setup for Breakout"
              },
              {
                "id": 141048348,
                "url": "https://finnhub.io/api/news?id=7172b274a14c0e365b0221f98cf8730f87f861736eeece3e6e1d313c5bc1f022",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $490.39, moving +2.38% from the previous trading session.",
                "category": "company",
                "datetime": 1785275405,
                "headline": "Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider"
              },
              {
                "id": 141043741,
                "url": "https://finnhub.io/api/news?id=7f74e4b608d0430ce273cd33af9179a12f910b9aa7dd3269cbb77c4b0b1085f6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1785247226,
                "headline": "Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for"
              },
              {
                "id": 141043769,
                "url": "https://finnhub.io/api/news?id=b7dde44202e682107701df8a3cf25cac7d7d55413e6642c4ec20852be2744635",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "category": "company",
                "datetime": 1785243604,
                "headline": "Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know"
              },
              {
                "id": 141044941,
                "url": "https://finnhub.io/api/news?id=85487e655fb89144a8a6f022c19cdb5c978e7d32417f8c31520957270297579f",
                "image": "https://image.cnbcfm.com/api/v1/image/108340810-260727-Chris_Young__Vertex_CEO.jpg?v=1785190743&w=1920&h=1080",
                "source": "CNBC",
                "related": "VRTX",
                "summary": "Vertex CEO Chris Young told Jon Fortt tax compliance is being remade by AI, e-invoicing mandates and agentic commerce – but tax has to stay deterministic, so AI wraps the engines rather than replacing them. He's targeting $60–70M in savings to fund that shift. Young grew up working class on Cleveland's east side, a Great Migration family – father in autos, mother working three jobs – before Princeton and a career at AOL, McAfee and Microsoft.",
                "category": "company",
                "datetime": 1785234037,
                "headline": "Chris Young, Vertex CEO: A Fortt Knox Conversation"
              },
              {
                "id": 141035245,
                "url": "https://finnhub.io/api/news?id=907644a0468d61ac054182ce249d9a1ef85614834d4d246abe2d6b7ed023a0a1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "VRTX heads into its Q2 earnings release with Trikafta, Alyftrek, Casgevy and Journavx in focus as investors watch product sales and updates on ongoing pipeline studies.",
                "category": "company",
                "datetime": 1785166320,
                "headline": "Vertex Gears Up to Report Q2 Earnings: What Can Investors Expect?"
              },
              {
                "id": 141033946,
                "url": "https://finnhub.io/api/news?id=75ff07118ffa82f1c08f586e8d6232740ba903a6eddbecfca1b3be71d8f36219",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1785160812,
                "headline": "Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?"
              },
              {
                "id": 141010849,
                "url": "https://finnhub.io/api/news?id=61caf6cd2d1aa2c47d5b115b8acad8415f768278eafa34f312a4ded1833d3fa7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "VANCOUVER, British Columbia, July 24, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) announces that it has engaged MCS Market Communication Service GmbH (“MCS”) (address: Rheinpromenade 13, 0789 Monheim am Rhein; email: info@mcsmarket.de) to provide marketing services for an expected term of 3 months, commencing July 27, 2026, provided that the term of the marketing services may be extended or shortened at the discretion of management",
                "category": "company",
                "datetime": 1784926800,
                "headline": "Vortex Energy Corp. Announces Marketing Program"
              },
              {
                "id": 140994788,
                "url": "https://finnhub.io/api/news?id=531056513eb02609f4a4938c9a9d323461a433a76b4cbd553c5d298c12047e7a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "With its first drug on the market and a pipeline full of catalysts, the company asks investors to weigh a powerful growth story against an elevated valuation and a history of volatility.",
                "category": "company",
                "datetime": 1784818856,
                "headline": "Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company?"
              },
              {
                "id": 140992567,
                "url": "https://finnhub.io/api/news?id=f03ef675567d5108e942c33fea0af0f892d3babe234791d60ea6de7bc0d32119",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, which has supported the industry’s returns lately - over the past six months, healthcare stocks have gained 10%, nearly mirroring the S&P 500.",
                "category": "company",
                "datetime": 1784802168,
                "headline": "3 Healthcare Stocks with Competitive Advantages"
              },
              {
                "id": 140989341,
                "url": "https://finnhub.io/api/news?id=9a4acf17d85cd62640b1ef99d26433eb4843ddd26ea54db4439b95b95e06927d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $472.57, marking a -1.96% move from the previous day.",
                "category": "company",
                "datetime": 1784757004,
                "headline": "Vertex Pharmaceuticals (VRTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know"
              },
              {
                "id": 140988043,
                "url": "https://finnhub.io/api/news?id=4e6b58aa0243c4cf3ed6fa01c255ff8093c21f5501c6043b24f8e69611512bd7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Analysts expect new details on the lead-up to the deal “are likely to reignite” investor scrutiny that Vertex overpaid in what’s poised to be its largest-ever transaction.",
                "category": "company",
                "datetime": 1784738880,
                "headline": "Vertex was sole bidder in high-premium Crinetics acquisition"
              },
              {
                "id": 140975311,
                "url": "https://finnhub.io/api/news?id=25ea968d0976819831cb67877ca7d310eb561e52b6e6376eb848ef60154d12c1",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/21/Russell-2000-Index--Text-On-Notebook-Wit.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Seven small-cap stocks have surged as much as 123% in early July on buyouts, FDA developments, refinancing deals and short squeezes.",
                "category": "company",
                "datetime": 1784649148,
                "headline": "These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why"
              },
              {
                "id": 140970568,
                "url": "https://finnhub.io/api/news?id=17b796c52376fef7d61ed6758f543a5b5122e8be4093a5b173e2914f2be71336",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "(American News Group News Commentary) For the millions of people who manage diabetes with daily insulin injections, the holy grail has always been the same: a therapy that senses blood sugar and releases the right amount of insulin on its own, the way a healthy pancreas does. A growing group of biotech companies is chasing that goal with cell-based therapies, and this week one small player took a concrete step toward making its version real.",
                "category": "company",
                "datetime": 1784638800,
                "headline": "A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up"
              },
              {
                "id": 140970448,
                "url": "https://finnhub.io/api/news?id=4a0e1ac981bb5a7f38fee8acbaf68052de3d913022a498bdaffa2648573b9719",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "(Bloomberg) -- The biotechnology sector is stealing the US IPO market thunder from artificial intelligence-related listings, delivering standout returns as bankers line up a steady stream of summer debuts.Most Read from BloombergYemen’s Houthis to Impose Maritime Blockade on Saudi ArabiaChina AI Sensation Moonshot’s Gamble on Big Models Pays OffTrump Vows 50% Tariff on Canadian Goods Using Depression-Era LawMoonshot’s Kimi K3 May Be More About Memory Than ComputeUS Strikes Iran in Escalating Cam",
                "category": "company",
                "datetime": 1784637325,
                "headline": "Biotech IPO Gains Crush AI Listings With Standout 55% Return"
              },
              {
                "id": 140969778,
                "url": "https://finnhub.io/api/news?id=27a8f9b4c11fb3341b7a9d59fe254f0b38844816434279378c40ce04a712ba81",
                "image": "https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp",
                "source": "ChartMill",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals offers affordable growth with strong double-digit earnings and revenue expansion, zero debt, and a P/E below the S&P 500 average—trading at a deep discount to biotech peers.",
                "category": "company",
                "datetime": 1784636429,
                "headline": "Vertex Pharmaceuticals (NASDAQ:VRTX): An Affordable Growth Stock Balancing Strong Fundamentals With Reasonable Valuation"
              },
              {
                "id": 140966272,
                "url": "https://finnhub.io/api/news?id=873f6ef6e8863740f15f5ee5dac12b06b5a4bce91785b0cbcd6cc716a92c8621",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $480.5, denoting a -1.06% move from the preceding trading day.",
                "category": "company",
                "datetime": 1784584806,
                "headline": "Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today"
              },
              {
                "id": 140958171,
                "url": "https://finnhub.io/api/news?id=92d5092f112f44af843f3884d48faf9004532046bab42282250b2a22dc512f2d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Earlier this month, the FDA expanded approval of Vertex Pharmaceuticals’ gene therapy Casgevy (exagamglogene autotemcel) to children aged 2 and older with sickle cell disease and transfusion-dependent thalassemia, following strong efficacy signals in two small pediatric trials. This milestone meaningfully widens access to a first-in-class gene therapy for very young patients, reinforcing Vertex’s role in genetic medicines beyond its cystic fibrosis core. We’ll examine how broadening...",
                "category": "company",
                "datetime": 1784538570,
                "headline": "How FDA’s Pediatric Expansion of Casgevy at Vertex Pharmaceuticals (VRTX) Has Changed Its Investment Story"
              },
              {
                "id": 140957169,
                "url": "https://finnhub.io/api/news?id=eff47664a09c223d3bd87244ea256a86d7edb50f9be4a91c0183fbb81ead926f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals' gene therapy exagamglogene autotemcel (Casgevy) has received expanded FDA approval. The approval now includes children as young as 2 years old with sickle cell disease or transfusion-dependent thalassemia. This decision broadens treatment options for a pediatric group with limited alternatives. For investors watching NasdaqGS:VRTX, the expanded approval highlights how Vertex Pharmaceuticals is building out its rare disease franchise around genetic medicines. The...",
                "category": "company",
                "datetime": 1784524037,
                "headline": "Vertex Pharmaceuticals (VRTX) Wins FDA Nod To Treat Children As Young As 2"
              },
              {
                "id": 140956306,
                "url": "https://finnhub.io/api/news?id=83d73f2ff98d0ae97212a4f0871c30b3aa6f32ee58d242286e4e3a28433d61cd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "The biotech's diversification efforts continue.",
                "category": "company",
                "datetime": 1784505900,
                "headline": "Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching"
              },
              {
                "id": 140921040,
                "url": "https://finnhub.io/api/news?id=b38cca16ff3fdab553b9d5e5467ff26d8301f3f124e2c0c76e4b155de1bc8e82",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like profitability concerns, rising costs, or shifts in market trends.",
                "category": "company",
                "datetime": 1784214322,
                "headline": "1 Nasdaq 100 Stock to Keep an Eye On and 2 We Question"
              },
              {
                "id": 140919919,
                "url": "https://finnhub.io/api/news?id=ac38e40815783f8ec5171d72b4c86aa0d5496672e10888f4bb0f5347b866864d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Get paid a guaranteed income on your Vertex shares today, which you keep no matter what, for agreeing to sell them at a higher price if the stock keeps climbing.",
                "category": "company",
                "datetime": 1784207177,
                "headline": "Collect 9.8% On VRTX Stock Now, And Still Keep 15% Of Upside"
              },
              {
                "id": 140921115,
                "url": "https://finnhub.io/api/news?id=c30edaca5af32f3105a0567a5af374e6b5c51828db4fe6b490b1d148d2a5a47e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
                "category": "company",
                "datetime": 1784206803,
                "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It"
              },
              {
                "id": 140919920,
                "url": "https://finnhub.io/api/news?id=22f201450e4146a22e8d333752623c653c83dfc64ed8ec26c95bd36b95ee5206",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Technical review to strengthen subsurface model and guide next phase of developmentVANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to provide a corporate update on the ongoing technical study being completed by Lonquist Field Service (Canada), ULC (“Lonquist”) at the Company’s Robinsons River Salt Project (the “Project”), located approximately 35 kilometres south of Stephenville, Newfoun",
                "category": "company",
                "datetime": 1784203200,
                "headline": "Vortex Energy Provides Corporate Update on Robinsons River Salt Project Technical Study"
              },
              {
                "id": 140918684,
                "url": "https://finnhub.io/api/news?id=c5cd568c38c82229699ecfeff65d5f3e8af22b1b318f0d131623d8f2582c384d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2190808580/image_2190808580.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "The curing sickle cell through gene therapy story is a long way from being written. But it’s for sure that it has not gone like some of its participants have wanted it to. Read more here...",
                "category": "company",
                "datetime": 1784187000,
                "headline": "The Battle For Sickle Cell"
              },
              {
                "id": 140925193,
                "url": "https://finnhub.io/api/news?id=a1e97ddb4115cd5f851ad1b2dcb8625c247944437da76f2f5a37275be9ebfa7d",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_4.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 7.55% on an annualized basis producing an average annual return of 19.41%. Currently, Vertex Pharmaceuticals has a market",
                "category": "company",
                "datetime": 1784135733,
                "headline": "$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today"
              },
              {
                "id": 140911439,
                "url": "https://finnhub.io/api/news?id=a706d9b34a32e9ee4e72c8bb0e5c93ecc188bc198255ecbd232c037a410bf5d7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "An ETF's label tells you the category, but the real story is always in the portfolio's actual shape.",
                "category": "company",
                "datetime": 1784132585,
                "headline": "IBB ETF Holds Fewer Bets Than You Think"
              },
              {
                "id": 140909807,
                "url": "https://finnhub.io/api/news?id=894eb83bae3b7701338821979d336d28e14b5029ab6a7dc8a0330d7df2b3d9fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the 10 affordable biotech stocks to buy right now. On July 6, Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) and Vertex Pharmaceuticals announced that both companies have agreed to a definitive agreement, according to which Vertex will acquire Crinetics Pharmaceuticals. The deal is priced at $85 a share in cash consideration, […]",
                "category": "company",
                "datetime": 1784124103,
                "headline": "Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal"
              },
              {
                "id": 140897048,
                "url": "https://finnhub.io/api/news?id=8fd522063fde651778f609334b93b87ac175d51b99792eac01e61e5ec2bdd003",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex's $10 billion acquisition may have spooked investors, given how rich it appeared to be.",
                "category": "company",
                "datetime": 1784031600,
                "headline": "Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals"
              },
              {
                "id": 140892612,
                "url": "https://finnhub.io/api/news?id=3d6b8baa9a83aa76e7cac3b939b0b62322f2dc6cbddd01beda9acf03fcca2fe6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) reached $480.25 at the closing of the latest trading day, reflecting a -1.06% change compared to its last close.",
                "category": "company",
                "datetime": 1783980006,
                "headline": "Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors"
              },
              {
                "id": 140891369,
                "url": "https://finnhub.io/api/news?id=cd9d911d1d1ddc04410b592e494aed229ad87f0921faa2794983c8582dbd1465",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, July 13, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) announces that it has closed its previously announced non-brokered private placement financing (the “Private Placement”). The Company issued an aggregate of 5,000,000 units of the Company (the “Units”) at a price of $0.30 per Unit for gross proceeds of $",
                "category": "company",
                "datetime": 1783979160,
                "headline": "Vortex Energy Corp. Announces Closing of LIFE Offering"
              },
              {
                "id": 140889916,
                "url": "https://finnhub.io/api/news?id=e8a7de07cc162dea1ae6251224928f62de69baad025c1e8b989c861cc24f2a14",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals recently announced its largest-ever acquisition.",
                "category": "company",
                "datetime": 1783968427,
                "headline": "Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?"
              },
              {
                "id": 140891092,
                "url": "https://finnhub.io/api/news?id=7de8e9d2f4590eeb57173c106d795ec9e57e4287831ea47e3a3f0eb5dc45f49e",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "UBS  analyst Michael Yee   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $545 to $585.",
                "category": "company",
                "datetime": 1783952283,
                "headline": "UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $585"
              },
              {
                "id": 140891370,
                "url": "https://finnhub.io/api/news?id=03bcc91f3ed155fa3ddcb91bbc261b06b7a6a3b1554a720faace2ae6851096e3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.",
                "category": "company",
                "datetime": 1783951045,
                "headline": "What to Expect From Vertex Pharmaceuticals' Next Quarterly Earnings Report"
              },
              {
                "id": 140891093,
                "url": "https://finnhub.io/api/news?id=fd93aff66889dc24055c8b99639e5acc340f6629383543951e341c24f0b63207",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Truist Securities  analyst Danielle Brill   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $542 to $560.",
                "category": "company",
                "datetime": 1783945862,
                "headline": "Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $560"
              },
              {
                "id": 140874823,
                "url": "https://finnhub.io/api/news?id=74393636e844e518614a2f2bbc4b00f4b95cda8bb29e624da6373305bfa8aab5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NasdaqGS:VRTX) received expanded FDA approval for CASGEVY, extending use to children as young as 2 years with sickle cell disease and beta thalassemia. The company also signed a Letter of Intent with Canadian national payers that outlines commercial access terms for ALYFTREK, its next generation cystic fibrosis therapy. These updates arrive as Vertex Pharmaceuticals trades around $485.39 and remains closely watched after a 140.0% return over the past 5 years and a...",
                "category": "company",
                "datetime": 1783826346,
                "headline": "Vertex (VRTX) Wins FDA Expansion For CASGEVY And Advances ALYFTREK In Canada"
              },
              {
                "id": 140873536,
                "url": "https://finnhub.io/api/news?id=e9086ad552f75890511f4f50816a1086a025168d4d5bcc85a6530a23c82a78c6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NASDAQ:VRTX) said it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, a transaction Vertex executives described as a strategic expansion into specialty endocrinology. On a conference call announcing the deal, Vertex CEO",
                "category": "company",
                "datetime": 1783803729,
                "headline": "Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse"
              },
              {
                "id": 140866271,
                "url": "https://finnhub.io/api/news?id=3474024df282bf83c2487827c06844fbdf81b888de20d743220ca244b809d07e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "It's been a volatile year for the company, but don't let that scare you away.",
                "category": "company",
                "datetime": 1783718400,
                "headline": "Is This Biotech Stock a Buy Near Its 52-Week High?"
              },
              {
                "id": 140865211,
                "url": "https://finnhub.io/api/news?id=c9b07089322e23d06265dae52c2992c333bdcda8fef02ebe98f458bef38d5d1f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "It is getting acquired by a larger firm in the sector.",
                "category": "company",
                "datetime": 1783711352,
                "headline": "Why This Pharmaceutical Stock Jumped Close to 100% This Week"
              },
              {
                "id": 140861703,
                "url": "https://finnhub.io/api/news?id=af70857a11cc855d135aa4dbacdfb09561eefbc7830e6114b9d2980a93d0ad6f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.",
                "category": "company",
                "datetime": 1783686601,
                "headline": "If You Invested $1000 in Vertex Pharmaceuticals a Decade Ago, This is How Much It'd Be Worth Now"
              },
              {
                "id": 140861704,
                "url": "https://finnhub.io/api/news?id=261335ddb3a4405ad09573cc88858404a83f044cb91dc30fe6fb403e911b1373",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "With its lead drug driving rapid growth and three more on deck, the biotech is betting it can outrun future competition and a history of volatility.",
                "category": "company",
                "datetime": 1783685653,
                "headline": "Beyond The Breakout Drug: Is BridgeBio Pharma Stock A Buy On Its Next Act?"
              },
              {
                "id": 140860831,
                "url": "https://finnhub.io/api/news?id=70bace5e39146e0e64ac0773b15c6a491cc88cb329eb3be14cd2305070834fcd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "A look at the company's history of deep drawdowns shows the real risk shareholders are carrying today.",
                "category": "company",
                "datetime": 1783683335,
                "headline": "The Long Climb Back For Ionis Stock"
              },
              {
                "id": 140859839,
                "url": "https://finnhub.io/api/news?id=cdd9c810230d73c852b260a9d4bceec99d4b0eebc8f9e6457c65267d2e0ad5c7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Additional blockbuster drugs may be on the horizon.",
                "category": "company",
                "datetime": 1783671900,
                "headline": "Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy?"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 4,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.2,
            "source_article_count": 91,
            "discarded_article_count": 66
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 23.6,
        "grade": "良好",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 2.2,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.2,
            "vcp_reason": "波幅收縮(13.8%→5.7%)；跌縮量(近10日5日)；站上MA50；Ready=Y；Confirm=N",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 1743350,
              "down_days": 5,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 1417730,
              "avg_vol_20": 1339495,
              "avg_vol_30": 1743350,
              "range_pct_10": 0.056645190403539075,
              "range_pct_20": 0.06835728732134379,
              "range_pct_30": 0.13842800215897755,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.8132216709209281,
              "dist_to_20d_high": 0.005692395422020102,
              "down_shrink_days": 5,
              "breakout_level_20d": 498.91,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.4092032646580057
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.8,
          "rsiKdjPoints": 4,
          "volumeWeight": 2,
          "maCrossPoints": 2.4,
          "shortRsiPoints": 1,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.6,
            "details": {
              "atrPct": 2.672425224853394,
              "turnoverUsdM": 492.2998749468,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.8,
          "stopLevels": {
            "symbol": "US.VRTX",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 469.5558,
            "strength_details": {
              "ma_score": 2,
              "atr_score": 2,
              "rsi_score": 3,
              "macd_score": 3,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.7,
            "stop_loss_percent": 5.3,
            "take_profit_price": 539.8184,
            "target_multiplier": 2.2,
            "technical_strength": 2.25,
            "take_profit_percent": 8.8
          },
          "positionPoints": 1.6,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.646444569928567,
          "stopLossPercent": 5.344850449706788,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.VRTX",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 100,
    "atr": {
      "atr": 13.2571,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.67
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 159.68
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.0535
    },
    "kdj": {
      "d": 56.29,
      "j": 95.72,
      "k": 69.43,
      "rule": "Cursor_18.24 K/D cross",
      "score": 6,
      "signal": "強金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "平衡",
      "score": 6,
      "value": 53.31
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 4,
      "trend": "弱勢",
      "value": 14020300,
      "recentSlope": -8130,
      "previousSlope": 280890
    },
    "rsi": 60.33,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 469.2697,
      "position": "SAR喺價下",
      "distancePct": 5.4,
      "previousTrend": "上升"
    },
    "ma50": 473.1562,
    "macd": {
      "macd": 1.9619797969711499,
      "trend": "強烈看漲",
      "signal": 1.6491968583541006,
      "histogram": 0.3127829386170493
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 8,
      "value": 480.9734,
      "position": "連續3日>VWAP",
      "consecutiveAbove": 3
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.75,
      "score": 2,
      "avgVolume": 1317605,
      "currentVolume": 992400
    },
    "derived": {
      "ma20": 480.836,
      "ma50": 473.1562,
      "prevClose": 484.03,
      "avgVolume10": 1391570,
      "avgVolume20": 1317605,
      "changePercent": 2.49,
      "avgVolumeForScore": 1317605
    },
    "ma_cross": {
      "ma20": 480.836,
      "ma50": 473.1562,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "接近",
      "score": 6,
      "prevMa20": 480.302,
      "prevMa50": 471.9792,
      "spreadPct": 1.62,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 468.9396,
      "upper": 492.7324,
      "position": "上半部"
    },
    "rsi_short": 68.94,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.75
    }
  }
}

Raw metrics JSON

 
{
  "close": 496.07,
  "volume": 992400,
  "changePercent": 2.49
}

Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank.ai provides research support only and does not provide financial advice or buy/sell recommendations.